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Diabetes mellitus affects 5% of the world’s population and requires constant 
monitoring to avoid fatality. Tight control of blood glucose levels has shown to reduce the 
long-term effects of diabetes. Finger-stick blood glucose measurements are the gold 
standard for glucose monitoring that are painful and only provide intermittent glucose 
values. Continuous glucose monitoring (CGM) is an improvement in this technology but 
is severely limited in its performance abilities beyond the currently approved implantation 
time lasting up to a week. CGM is still performed as an adjunct to finger-stick 
measurements since they are unreliable even during the approved usage durations. 
Implantation of a biomaterial induces a wound (catheter, hernia meshes, etc.) or 
disturbance in local tissue (contact lens, etc.). Wound healing response in the host 
mediates the formation of scar tissue and healing of the injury site. Host foreign body 
response (FBR) deviates from its healing response in the presence of a foreign body i.e, 
an implant, and tries to isolate it from the host via fibrous encapsulation. FBR is 
considered as one of the primary reasons for CGM sensor failure. FBR encapsulates the 
sensor implant, creating a barrier between the sensing electrode and essential analytes 
(glucose, oxygen, etc.) required for measuring glucose levels. This phenomenon results 
in painful and expensive CGM sensor replacements.  
Work described in this dissertation focuses on improving the clinical performance 
of CGM sensors by extending their functional lifetimes. Combination device strategies 
involving the use of a drug (dexamethasone, etc.), or a biologic (VEGF, siRNA, etc.), or 




dissertation, we targeted mast cells that are believed to orchestrate the FBR by 
secreting several key granules containing inflammatory cytokines, vasodilators, 
chemokines, etc. that result in an increased influx of inflammatory cells to the wound 
site. A novel tyrosine kinase inhibitor- masitinib was used to target the c-KIT receptor on 
the cell surface of mast cells. Stem cell factor and its ligand c-KIT are considered critical 
for mast cell survival, proliferation, and degranulation and the hypothesis driving this 
research is that targeting mast cell degranulation via the c-KIT pathway results in a 
reduced foreign body response.   
To test our hypothesis, we developed a local drug delivery formulation comprised 
of PLGA microsphere drug carriers embedded in a PEG matrix around implants. The 
effect of the drug was initially evaluated in wild-type (mast cell competent) and sash 
(mast cell-deficient) mice for up to 28 days. The results from these studies confirmed 
previous claims that mast cells play an important role in mediating FBR-associated 
fibrosis around implanted biomaterials and that the use of a mast cell stabilizing tyrosine 
kinase inhibitor reduced fibrous capsule thickness around implants in wild-type mice but 
had no effect in sash mice. The drug-releasing coating was then tested in CGM sensors 
in a wild-type murine percutaneous model for 21 days. Results from the CGM study 
indicate that drug-releasing coated sensors exhibit relatively stable response compared 
to control implants, suggesting that reduced fibrosis resulting from stabilizing mast cells 
results in improving CGM performance. The translation of these results to human 
subjects would enable better control of diabetes and provide the ability to better 
diagnose long-term effects of diabetes through long-term continuous glucose monitoring. 
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PREFACE 
Host reaction to an implanted foreign body remains one of the foremost 
challenges hindering the extension of in vivo operational lifetimes of continuous glucose 
monitoring (CGM) sensors. This research focuses on locally controlling early-stage mast 
cell reactions inducing the host reaction around the implanted CGM sensor. Many 
previous elaborate and sophisticated methods to address the foreign body response 
(FBR) issue have exploited drugs, designs, and materials, but they have not addressed 
the biological source of the problem. The central theme of our proposal is the local 
delivery of the tyrosine kinase inhibitor (TKI), masitinib, to inhibit mast cell c-KIT 
and FCεRI receptors, thereby stabilizing these potent inflammatory mediators 
around the implant. This will serve to reduce the intensity of the acute inflammatory 
reaction, attenuating cytokine releases that attract fibroblasts to sites to prompt 
production of a fibrous capsule. Drug-loaded degradable polymer microspheres in 
temporary polymer carrier coatings on the CGM implant surface constitute the local 
controlled release matrix. The coating-modified CGM devices have been exploited both 
as an analytical tool to gauge the intensity of the FBR by measuring the change in CGM 
output signals in situ and also to report glucose changes over time as required. 
Innovation resides in the use of locally delivered TKI, specifically masitinib, to 
control the tissue site reactivity. This drug class has not been used in this sensor 
application before, either to control mast cell (MC) behavior, or in combination device 
formulations in the context of the FBR or any implant application. Our focus on MC-
centered control points in inflammation and the FBR is not novel, but the focus on 
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control of MC behavior locally around implants, and CGMs, is innovative. Exploiting the 
W-sash MC-deficient mouse compared to wild-type implant models under local drug 
control exploits this previous MC-FBR connection in an innovative mechanistic way 
toward elucidating their involvement in the FBR.  Lastly, the focus on a clinically 
important but modest, incremental improvement for CGM performance in vivo (i.e., 
increasing sensor performance from 5-7 days to 14-21 days) is a much more realistic 
goal that should provide profound clinical impact if achieved, compared to 4 decades of 
unrealized claims to extend implant life indefinitely. 
In this dissertation, Chapter 2 is a review of combination medical devices: 
approved clinical implants with functions that are modified by the addition of add-on drug 
loads. This chapter (accepted book chapter published as Avula M, Grainger DW. 
Addressing medical device challenges with drug/device combination. In: Siegel R, Lyu 
SP, editors. Drug-Device Combinations for Chronic Diseases. New York: Jon Wiley & 
Sons; 2013.) serves to introduce the reader to the concept of combination medical 
devices and the aspects of their design and pharmacology in modern clinical use. It 
gives a comprehensive review of FDA-approved combination devices focusing on the 
different host responses (inflammatory response, thrombosis, coagulation, and infection 
mitigation) to implantable medical devices and the drug-device combination strategies 
employed to overcome the host response. Drug-eluting stents, antimicrobial catheters, 
vascular grafts with antithrombotic coatings, and orthopedic drug-eluting implants are 
mainly discussed with the various pharmaceutical drugs and formulation strategies 
involved. This chapter further leads us to possible future strategies that are in 
development to provide a more personalized strategy for the next generation of 
combination devices.  
Chapter 3 is a reprint of a published full manuscript in the leading journal, 
Biomaterials (M. Avula, A. Rao, L.D. McGill, D.W. Grainger, F. Solzbacher, “Modulation 
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of the foreign body response to implanted sensor models through device-based delivery 
of the tyrosine kinase inhibitor, masitinib,” Biomaterials, published, 2013) and describes 
release of a tyrosine kinase inhibitor – masitinib – from the sensor implant to target 
tissue resident mast cells as key mediators of the FBR.  Model implants are coated with 
a composite polymer hydrophilic matrix that rapidly dissolves upon tissue implantation to 
deposit slower-degrading polymer microparticles containing masitinib.  Matrix dissolution 
limits coating interference with sensor function while establishing a local controlled-
release delivery depot formulation to alter implant tissue pharmacology and addressing 
the FBR. Drug efficacy was evaluated in a murine subcutaneous pocket implant model. 
Drug release extends to more than 30 days in vitro. The resulting FBR in vivo, evaluated 
by implant capsule thickness and inflammatory cell densities at 14, 21, and 28 days, 
displays statistically significant reduction in capsule thickness around masitinib-releasing 
implant sites compared to control implant sites. 
Chapter 4 (Avula M, Rao AN, McGill LD, Grainger DW, Solzbacher F. Foreign 
Body Response to Implanted Biomaterials in a Mast Cell-deficient Kitw-Sh Murine Model. 
Acta Biomater 2013; Submitted) is a reprint of a full manuscript submitted to Acta 
Biomaterialia and describes the modulation of foreign body response in the absence of 
mast cells in a mast cell-deficient sash mouse model. Mast cells are recognized for their 
functional role in wound healing, allergic, and inflammatory responses, host responses 
that are frequently detrimental to implanted biomaterials if extended beyond acute 
reactivity.  These tissue reactions are especially impacting to the performance of sensing 
implants such as continuous glucose monitoring (CGM) devices.  That effective 
blockade of mast cell activity around implants could alter the host foreign body response 
(FBR) and enhance the in vivo lifetime of these implantable devices motivated this study. 
Stem cell factor (SCF) and its ligand c-KIT receptor are critically important for mast cell 
survival, differentiation, and degranulation.  Therefore, a mast cell-deficient sash mouse 
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model was used to assess mast cell relationships to CGM implants.  Additionally, local 
delivery of a tyrosine kinase inhibitor (TKI) that inhibits c-KIT activity was also used to 
evaluate the role of mast cells in modulating the FBR.  Model sensor implants 
comprising polyester fibers coated with a rapidly dissolving polymer coating containing 
drug-releasing degradable microspheres were implanted subcutaneously in sash mice 
for various time points, and the FBR was evaluated for chronic inflammation and fibrous 
capsule formation around the implants. No significant differences were observed in the 
foreign body capsule formation between control and drug-releasing implant groups in 
mast cell-deficient mice. However, fibrous encapsulation was significantly greater around 
the drug-releasing implants in sash mice compared to drug-releasing implants in wild-
type (e.g., mast cell competent) mice.  These results provide insights into the role of 
mast cells in the FBR, suggesting that mast cell deficiency provides alternative pathways 
for host inflammatory responses to implanted biomaterials.  
 Chapter 5 (Local release of masitinib affects implantable continuous glucose 
sensor performance) describes the use of mast cell-targeting tyrosine kinase inhibitor, 
masitinib, released from polymer microspheres delivered from the surfaces of 
commercial CGM needle-type implanted sensors. Targeting the mast cell c-Kit receptor 
and inihibting mast cell activation and degranulation, the local masitinib delivery around 
the CGM sought to reduce fibrosis around the sensor and extend its functional lifetime in 
subcutaneous sites. Drug-releasing and control CGM implants were tested in murine 
percutaneous implant studies for 21 days continuously.  Drug-releasing implants showed 
reduced fibrosis around implant sites and relatively stable sensor responses over the 
period of the study compared to blank microsphere controls. 
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Chapter 6 produces some analysis of current deficiencies in the approach based 
on the results reported and describes follow-on experiments that would be prudent to 
pursue in this strategy with potentially fruitful new results. 
CHAPTER 1 
BACKGROUND AND INTRODUCTION 
Implantable medical devices (IMDs) undergo a spontaneous host-mediated 
foreign body response (FBR) upon implantation as a result of local tissue disturbance or 
wound creation. FBR is the aberrant wound healing mechanism seeking ultimately to 
eliminate foreign objects from host tissue sites to restore normal wound repair and tissue 
remodeling. The FBR is mediated by complex spatial and temporal cellular and protein 
components recruited to the wound site as a part of initially normal inflammatory 
processes in acute wounding. However, the FBR results from abnormal chronic 
inflammatory processes at the wound site resulting from implant placement. Initial 
biochemical and physical cellular events seeking to degrade, engulf, and eliminate the 
foreign body become frustrated if sustained beyond the acute temporal window. This 
inability to physically expel the foreign body from the tissue site leads eventually in 
chronic phases to fibrous encapsulation of the foreign object. In the case of sensor IMDs 
such as the clinically important continuous glucose monitoring (CGM) sensors, FBR 
results in unreliable tissue glucose measurements, requiring frequent CGM 
replacements.  This frequent tissue replacement makes CGMs expensive, inconvenient, 
and uncomfortable to the user.  Since CGM sensors have shown significant reduction in 
glucose excursions in chronic diabetic patients, efforts to extend their performance and 
reliability in tissue sites are warranted.  These can be approached through device 
engineering, redesign, signal processing, and local pharmacologic strategies that modify 
the reactivity of the local tissue site.  
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1.1 Diabetes and Glucose Monitoring Significance   
Nearly 350 million people (5% of world population) suffer from diabetes 
worldwide [1], including the 25.8 million Americans (8.3% of the population) who require 
regular glucose monitoring. Treatment has direct and indirect costs of about $218 billion 
annually (2007) [2]. The rate of diabetes incidence in adults aged 18 or above in the 
United states has increased from 4.5% in 1990 to 8.2% in 2010 [3]. Tight regulation of 
blood glucose has been convincingly shown to reduce diabetes morbidity and mortality 
[4], leading to a standard of care that demands intensive glucose monitoring. This has 
traditionally used painful, invasive, and costly percutaneous sampling (i.e., finger sticks) 
through skin to extract blood that is measured on a hand-held calibrated monitor.  
Estimates are that 1.4 million diabetics (1.1 million Type 1 and nearly 0.3 million Type 2) 
in the US use insulin and measure blood glucose levels at least twice daily [5]. 
Innovations that improve the ease, convenience, access, compliance, and routine of 
glucose monitoring are needed. Patient avoidance of “finger sticks” is regularly attributed 
to diabetic noncompliance with glucose monitoring, and costly morbidities and mortalities 
associated with poor glucose control [6].  
A miniature implantable electrical transducer to monitor glucose continuously and 
remotely was first developed by Updike and Hicks [6] in 1967. Many of their concepts 
were based on glucose oxidase electrode designs described by Clark in 1956 [7-9]. In 
the early 1970s, several groups reported progress with glucose electrodes, including 
Soeldner et al., [10], Bessman et al., [11, 12] Gough and Andrade [13], and Williams et 
al., [14]. The mid-1970s saw the emergence of continuous glucose monitoring (CGM) via 
extrapolation of blood through a double-lumen catheter, used for the development of 
glucose sensor-controlled insulin infusion systems by Albisser, Leibel, et al. [15, 16] and 
by Clemens, Pfeiffer, et al. [17, 18].  Less exotic, more routine continuous glucose 
monitoring systems were produced in the 1990s, with the first reports on CGM by 
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subcutaneous microdialysis implants in 1992 [19, 20]. Subcutaneous implanted needle-
type CGM glucose sensing systems were available in 1999 [21-24].  
1.2 Continuous Glucose Monitors (CGMs)  
Currently, four subcutaneous CGM systems are approved and marketed with 
“real-time” glucose reporting every 1–5 minutes, and with alarm functions for hypo- and 
hyperglycemia [25, 26]. Three are needle-type subcutaneous designs:  the Freestyle 
Navigator (Abbott Diabetes Care, Alameda, CA), the Guardian Real-Time (Medtronic 
MiniMed, Northridge, CA), [27-29] and the Dexcom SEVEN (Dexcom, San Diego, CA). 
The fourth (GlucoDay, Menarini Diagnostics) is a microdialysis-type sensor.  All measure 
glucose in situ amperometrically via the classic Clark glucose-oxidase reaction shown 
below [4-6].  
 
CGMs are now used internationally by thousands of diabetic patients for daily 
glucose monitoring, particularly for asymptomatic hypoglycemia or rapidly fluctuating 
blood sugars (so-called “brittle” patients). Given this explosion in CGM use, the current 
performance issues dogging CGMs are notable: 
• Up to 21% CGM inaccuracy when compared with actual plasma glucose values, 
(expressed as mean absolute difference, i.e., [CGM glucose − plasma 
glucose]/plasma glucose) [30, 31].  Assay inaccuracy is even more profound in 
the hypoglycemic range or during rapid fluctuations in plasma glucose [32]. Lag 
times between physiologic glucose and instrumental delay inherent to current 
real-time CGMs contribute to CGM inaccuracy [33].  
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• Costs of CGM devices are a major downside. CGM monitoring costs about 
$4,930–7,120 per person-year compared with $550–2,740 for traditional self-
monitoring using finger sticks [5]. CGMs have been FDA-approved only for 
short-term, transient implant use, often using traditional finger sticks as a 
required “back-up” control [34]. Part of current CGM cost issue is the FDA 
mandate for CGM removal and replacement every 3-7 days [34, 35].  
• All four FDA-approved sensors exhibit instability over the approved implantation 
and sensing period (3-7 days), and their calibration is thought to be good for only 
12 hours [25]. Also, many of the electrochemical sensors exhibit a “run-in period” 
in which the sensitivity drops by 10-30% immediately after implantation [25, 36, 
37], followed by a period of stability that lasts 1 to 7 days before removal and 
costly replacement. 
1.3 CGM Performance Issues and Current Combination 
Device Strategies  
Clinical realization of improved implantable glucose sensors with extended 
lifetimes in vivo (>1 week) remains elusive primarily due to the host’s acute and chronic 
foreign body response (FBR) to the implanted sensor [38, 39]. CGM sensor biofouling, 
including protein adsorption on or infiltrated into the implanted sensors, as well as 
inflammatory wound-site reactions that limit analyte diffusion into the CGM contribute to 
the observed decrease in sensitivity upon acute implantation [37, 39, 40].  In addition to 
ubiquitous sensor fouling, the host inflammatory response to the implanted foreign body 
produces a sustained cascade of cellular reactions that alter the local environment 
around the implant, modify local metabolism and homeostasis, and trigger a departure 
from normal wound healing.  Leukocyte and mast cell invasion proceeds to fibroblast 
recruitment and proliferation. Release of inflammatory cytokines like IL-4 and IL-13 
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accelerate the recruitment of inflammatory and immune cells to the site of implant [41]. 
This further results in an intense expression of collagens around the implant within days 
of implantation. This excess connective tissue is rapidly remodeled into a dense fibrous 
capsule (fibrosis) that “walls off” the implant, separating the sensor from its physiological 
surroundings after 7-10 days of subcutaneous implantation. This foreign body capsule is 
the hallmark of the FBR, and a primary barrier to sustained CGM function. Despite 
intensive research over two decades, CGM glucose sensing performance under 
sustained chronic implantation (>14 days) remains a major challenge. 
As a result of sustained, persistent host tissue assault, continuous glucose 
monitoring exhibits substantial clinical performance issues, limiting patient utility and 
FDA approvals for long-term implant use. The host foreign body response (FBR) to 
implanted devices is often the limiting issue to implant longevity and performance [41]. 
Nonetheless, as a real-time in vivo data-reporting implant, the CGM provides a unique 
reporting tool in research to monitor and report real-time in vivo responses to both the 
implant’s acute phase host reaction as well as chronic host-implant integration reactions. 
That is, the implanted CGM provides both a relevant clinical metric, i.e., glucose 
determinations, and also an analytical metric, i.e., sensor signal fluctuations and 
attenuation corresponding to acute host inflammatory and more chronic foreign body 
response. This provides unique implant site information on the host response to the 
device and local physiology. Such an approach has been exploited by Reichert [37] and 
Klueh [42, 43] in producing new information on host tissue responses to CGMs in order 
to supply new rational design criteria for CGM improvements.   
The focus on reducing sensor surface fouling in vivo has predominantly been 
accomplished by applying specific coatings to sensor surfaces to inhibit protein 
adhesion. Hydrogels, polymers, flow-based systems, surfactants, naturally derived 
materials, and others have been used with only limited effectiveness in vivo [39, 
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44].  Modifying the CGM into a combination device that releases drug locally from the 
implant seeks to overcome these limitations [45-48]. Surface coatings containing nitric 
oxide [49-51], dexamethasone [45, 52, 53], and vascular endothelial growth factor 
(VEGF) [54, 55] attempt to limit biofouling while exploiting a local pharmacological 
strategy for modulating the intensity of the acute phase inflammatory reaction. Each 
locally released drug has formulation, loading and stability issues, different potencies, 
and different targets: dexamethasone seeks to inhibit fibroblast production of collagen 
around the sensor, while VEGF prompts local angiogenesis to make the FBR fibrotic 
capsule around the sensor effectively permeable, sufficiently perfused for glucose 
transport.  Significantly, these drug-release approaches have addressed cell targets and 
behaviors well downstream, and temporally and spatially distinct from the early acute-
phase FBR mast cell and leukocyte initiators around the implant.  
1.4 Role of Mast Cells in the Foreign Body Reaction to CGMs 
Mast cells (MC) play an important critical role in mediating acute phases of the 
tissue inflammatory response following sensor implantation: they are located 
perivascularly throughout all tissues and are mobilized during any inflammatory 
response [56].  MC degranulation of histamine and other pro-inflammatory mediators 
including heparin, cytokines (TNF-alpha), chemokines, and many proteases together 
with fibrinogen adsorption are recognized as powerful inducers of acute inflammatory 
responses to implanted biomaterials [57, 58].  MC-released cytokines and chemotaxis 
along with histamine and serotonin result in vasodilation and increased recruitment of 
phagocytes to the implant site. Their connection with the foreign body reaction is 
recognized [47, 48, 59]. Figure 1.1 illustrates mast cell degranulation in the presence of 
an allergen or foreign antigen. 
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Specific to CGMs, Klueh et al. [42] have recently compared in vivo CGM sensor 
implant performance in both wild-type and MC-deficient mice. Significantly, they 
confirmed based on CGM signal-to-noise ratio (S/N) and analyte response time as a 
function of implant time that MCs play a major role in the host FBR around CGMs.  
Importantly, this was linked to subsequent fibrous capsule formation around the CGM 
that impedes sensor function [42]. 
The operative mechanism behind apparent MC regulation of the host FBR has 
been elusive.  One new clue is that stem cell factor (SCF), the ligand of the MC-specific 
c-KIT tyrosine kinase receptor, is an important growth factor for MC survival, 
proliferation, differentiation, and degranulation processes [60]. The link between the MC-
specific SCF/MC c-KIT pathway and the intensity of acute phase of the inflammatory 
response is critical in MC function and degranulation reactions [60]. Central to the 
research in this dissertation, recent work shows that masitinib, a newly screened 
tyrosine kinase inhibitor (TKI), is effective in inhibiting the SCF receptor c-KIT on mast 
cells and is a potent inducer controlling MC reactivity [61, 62] by binding competitively to 
the ATP binding c-KIT receptor, and blocks its critical tyrosine kinase signaling activity. 
Importantly, this drug action stabilizes mast cells from degranulating or 
activating.  
A recent study [61] concludes that masitinib is a potent TKI that stabilizes mast 
cell reactivity both in vitro and in vivo when compared to imatinib mesylate - another 
widely used TKI to inhibit c-KIT [63]. As an indicator of common TKI bioactivity 
pathways, masitinib mesylate has already been shown to reduce production of 
extracellular matrix and prevent the development of experimental nonimplant fibrosis 
[64]. Nonetheless, masitinib is selective in inhibiting recombinant human c-KIT receptor 
(IC50 200	 ± 40nM), and platelet-derived growth factor receptor (PDGFR) while weakly 
inhibiting other type III tyrosine kinase receptors, including fibroblast growth factor 
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receptor 3 (FGFR3) and FCεRI receptor. Imatinib inhibits a broader range of receptors 
[61]. These receptors when bound to ligands like IgE, SCF, C3a, PAMPs etc., result in 
mast cell activity and degranulation [65], leading to increased inflammatory cell activity.  
Masitinib is currently in clinical trials as an oral therapeutic for Alzheimer’s disease [66], 
pancreatic cancer [67], canine mastocytosis [62], gastro-intestinal stromal tumors [68], 
and rheumatoid arthritis [69].  
Masitinib has been found to be effective against mast cell activity and has been 
found to have very less toxicity in mouse models [61] as it has high specificity for its 
target receptor, c-Kit. The structure of masitinib is shown in Figure 1.2. 
Our hypothesis is that stabilizing and avoiding degranulation of mast cells 
around the site of implantation could delay the cascade of events in the foreign 
body response to the host, thereby increasing the useful lifetime of the implants. 
To validate our hypothesis technically, a glucose sensor capable of continuous glucose 
monitoring (CGM) is coated with a composite polymer matrix comprising soluble PEG 
loaded with degradable PLGA/PLA microporous microspheres containing masitinib. This 
strategy produces a combination device for subcutaneous use, seeking to alter the local 
wound bed pharmacology by local drug release over extended time periods. The 
strategy intends to reduce mast cell reactivity, degranulation, and inflammatory 
responses leading to the FBR. Both model sensor implants (model polymer fibers of the 
same dimensions as the CGM implant) and functional human CGM devices are coated 
with this matrix and implanted in a murine subcutaneous implant model and the effect of 
masitinib and mast cell stabilization on FBR and the resulting CGM response are 
evaluated.   
Model sensor implants were tested in C57BL/6 mice and their mast cell-deficient 
mutant knockout strain (B6.Cg-KitW-sh/HNihrJaeBsmGlliJ). These models were used 
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before to compare the effects of mast cells on CGM sensor and hence were chosen for 







Figure 1.1: Mast cell degranulation in the presence of a foreign object or allergen 
 





[1] Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, 
regional, and global trends in fasting plasma glucose and diabetes prevalence since 
1980: systematic analysis of health examination surveys and epidemiological studies 
with 370 country-years and 2.7 million participants. The Lancet. 2011;378:31-40. 
[2] Centers for Disease Control and Prevention. National diabetes fact sheet: national 
estimates and general information on diabetes and prediabetes in the United States. In: 
Services DoHaH, editor. Atlanta, GA: U.S.: Centers for Disease Control and Prevention; 
2011. 
[3] CDC. Increasing Prevalence of Diagnosed Diabetes — United States and Puerto 
Rico, 1995–2010.  Morb Mortal Wkly Rep: CDC; 2012. 
[4] Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Monitoring blood 
glucose control in diabetes mellitus: a systematic review. Health Technol Assess. 
2000;4:i-iv, 1-93. 
[5] Pham M. Medtronic diabetes: sizing the market for realtime, continuous blood 
glucose monitors from MDT, DXCM, and ABT. HSBC Global Research; 2006. 
[6] Updike SJ, Hicks GP. The enzyme electrode. Nature. 1967;214:986-8. 
[7] Clark Jr. LC. Monitor and Control of Blood and Tissue Oxygen Tensions. ASAIO J. 
1956;2:41-8. 
[8] Clark Jr. LC. Membrane Polarographic Electrode System and Method With 
Electrochemical Compensation. United States: Leland Jr., Clark C.; 1970. 
[9] Clark Jr. LC. How the first enzyme electrode was invented. Biosens Bioelectron. 
1993;8. 
[10] Chang KW, Aisenberg S, Soeldher JS, Hiebert JM. Validation and Bioengineering 
Aspects of An Implantable Glucose Sensor. ASAIO J. 1973;19:352-60. 
[11] Bessman SP, Schultz RD. Progress toward a glucose sensor for the artificial 
pancreas. Adv Exp Med Biol. 1974;50:189-96. 
[12] Layne EC, Schultz RD, Thomas LJ, Slama G, Sayler DF, Bessman SP. Continuous 
extracorporeal monitoring of animal blood using the glucose electrode. Diabetes. 
1976;25:81-9. 
[13] Gough DA, Andrade JD. Enzyme Electrodes. Science. 1973;180:380-4. 
[14] Williams DL, Doig AR, Korosi A. Electrochemical-enzymatic analysis of blood 
glucose and lactate. Anal Chem. 1970;42:118-21. 
[15] Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial 
endocrine pancreas. Diabetes. 1974;23:389-96. 
11 
 
[16] Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, et al. Clinical 
control of diabetes by the artificial pancreas. Diabetes. 1974;23:397-404. 
[17] Pfeiffer EF, Thum C, Clemens AH. The artificial beta cell--a continuous control of 
blood sugar by external regulation of insulin infusion (glucose controlled insulin infusion 
system). Horm Metab Res. 1974;6:339-42. 
[18] Fogt EJ, Dodd LM, Jenning EM, Clemens AH. Development and evaluation of a 
glucose analyzer for a glucose controlled insulin infusion system ((Biostator). Clin Chem. 
1978;24:1366-72. 
[19] Bolinder J, Ungerstedt U, Arner P. Microdialysis measurement of the absolute 
glucose concentration in subcutaneous adipose tissue allowing glucose monitoring in 
diabetic patients. Diabetologia. 1992;35:1177-80. 
[20] Bolinder J, Ungerstedt U, Arner P. Long-term continuous glucose monitoring with 
microdialysis in ambulatory insulin-dependent diabetic patients. Lancet. 1993;342:1080-
5. 
[21] Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring 
used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. 
Diabetes Res Clin Pract. 1999;46:183-90. 
[22] Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, et al. 
Continuous subcutaneous glucose monitoring in children with type 1 diabetes. 
Pediatrics. 2001;107:222-6. 
[23] Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved 
metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. 
Pediatrics. 2003;111:933-8. 
[24] Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, et al. Use of the 
Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated 
diabetes: a randomized controlled trial. Mayo Clinic proceedings Mayo Clinic. 
2004;79:1521-6. 
[25] Wilson GSZ, Y. Introduction to the Glucose Sensing Problem.  In Vivo Glucose 
Sensing. Hoboken, NJ: John Wiley; 2010. 
[26] Liao KC, Hogen-Esch T, Richmond FJ, Marcu L, Clifton W, Loeb GE. Percutaneous 
fiber-optic sensor for chronic glucose monitoring in vivo. Biosens Bioelectron. 
2008;23:1458-65. 
[27] Jungheim K, Wientjes K, Heinemann L, Lodwig V, Koschinsky T, Schoonen A. 
Subcutaneous continuous glucose monitoring. Diabetes Care. 2001;24:1696. 
[28] Koschwanez H, Reichert W. In vitro, in vivo and post explantation testing of glucose-




[29] Wilson G, Hu Y. Enzyme-based biosensors for in vivo measurements. Chem Rev. 
2000;100:2693-704. 
[30] Hirsch IB. Realistic Expectations and Practical Use of Continuous Glucose 
Monitoring for the Endocrinologist. J Clin Endocrinol Metab. 2009;94:2232-8. 
[31] Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical 
and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31:1160-
4. 
[32] Wentholt IM, Hoekstra JB, Devries JH. Continuous glucose monitors: the long-
awaited watch dogs? Diabetes Technol Ther. 2007;9:399-409. 
[33] Wentholt IM, Hart AA, Hoekstra JB, Devries JH. Relationship between interstitial 
and blood glucose in type 1 diabetes patients: delay and the push-pull phenomenon 
revisited. Diabetes Technol Ther. 2007;9:169-75. 
[34] Burge MR, Mitchell S, Sawyer A, Schade DS. Continuous glucose monitoring: the 
future of diabetes management. Diabetes Spectrum. 2008;21:112. 
[35] Kondepati VR, Heise HM. Recent progress in analytical instrumentation for glycemic 
control in diabetic and critically ill patients. Anal Bioanal Chem. 2007;388:545-63. 
[36] Gifford R, Kehoe J, Barnes S, Kornilayev B, Alterman M, Wilson G. Protein 
interactions with subcutaneously implanted biosensors. Biomaterials. 2006;27:2587-98. 
[37] Wisniewski N, Moussy F, Reichert W. Characterization of implantable biosensor 
membrane biofouling. Fresenius' J Anal Chem. 2000;366:611-21. 
[38] Frost MC, Meyerhoff ME. Implantable chemical sensors for real-time clinical 
monitoring: progress and challenges. Curr Opin Chem Biol. 2002;6:633-41. 
[39] Wilson GS, Gifford R. Biosensors for real-time in vivo measurements. Biosens 
Bioelectron. 2005;20:2388-403. 
[40] Gerritsen M, Jansen JA, Lutterman JA. Performance of subcutaneously implanted 
glucose sensors for continuous monitoring. Neth J Med. 1999;54:167-79. 
[41] Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. 
Semin Immunol. 2008;20:86-100. 
[42] Klueh U, Kaur M, Qiao Y, Kreutzer DL. Critical role of tissue mast cells in controlling 
long-term glucose sensor function in vivo. Biomaterials. 2010;31:4540-51. 
[43] Klueh U, Dorsky DI, Kreutzer DL. Enhancement of implantable glucose sensor 
function in vivo using gene transfer-induced neovascularization. Biomaterials. 
2005;26:1155-63. 
[44] Wisniewski N, Reichert M. Methods for reducing biosensor membrane biofouling. 
Colloids Surf B Biointerfaces. 2000;18:197-219. 
13 
 
[45] Hickey T, Kreutzer D, Burgess D, Moussy F. Dexamethasone/PLGA microspheres 
for continuous delivery of an anti-inflammatory drug for implantable medical devices. 
Biomaterials. 2002;23:1649-56. 
[46] Hickey T, Kreutzer D, Burgess D, Moussy F. In vivo evaluation of a 
dexamethasone/PLGA microsphere system designed to suppress the inflammatory 
tissue response to implantable medical devices. J Biomed Mater Res. 2002;61:180-7. 
[47] Ward WK, Wood MD, Casey HM, Quinn MJ, Federiuk IF. The effect of local 
subcutaneous delivery of vascular endothelial growth factor on the function of a 
chronically implanted amperometric glucose sensor. Diabetes Technol Ther. 
2004;6:137-45. 
[48] Ward WK, Troupe JE. Assessment of chronically implanted subcutaneous glucose 
sensors in dogs: The effect of surrounding fluid masses. ASAIO J. 1999;45:555-61. 
[49] Nichols SP, Le NN, Klitzman B, Schoenfisch MH. Increased In Vivo Glucose 
Recovery via Nitric Oxide Release. Anal Chem. 2011;83:1180-4. 
[50] Nablo BJ, Prichard HL, Butler RD, Klitzman B, Schoenfisch MH. Inhibition of 
implant-associated infections via nitric oxide release. Biomaterials. 2005;26:6984-90. 
[51] Hetrick EM, Prichard HL, Klitzman B, Schoenfisch MH. Reduced foreign body 
response at nitric oxide-releasing subcutaneous implants. Biomaterials. 2007;28:4571-
80. 
[52] Bhardwaj U, Sura R, Papadimitrakopoulos F, Burgess DJ. Controlling acute 
inflammation with fast releasing dexamethasone-PLGA microsphere/pva hydrogel 
composites for implantable devices. J Diabetes Sci Technol. 2007;1:8-17. 
[53] Ju YM, Yu B, West L, Moussy Y, Moussy F. A dexamethasone-loaded PLGA 
microspheres/collagen scaffold composite for implantable glucose sensors. J Biomed 
Mater Res A. 2010;93:200-10. 
[54] Golub JS, Kim Y-t, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, et al. Sustained 
VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart 
Circ Physiol. 2010;298:H1959-H65. 
[55] Sung J, Barone PW, Kong H, Strano MS. Sequential delivery of dexamethasone 
and VEGF to control local tissue response for carbon nanotube fluorescence based 
micro-capillary implantable sensors. Biomaterials. 2009;30:622-31. 
[56] Krishnaswamy G, Ajitawi O, Chi DS. The human mast cell: an overview. Methods in 
molecular biology (Clifton, NJ). 2006;315:13-34. 
[57] Zdolsek J, Eaton J, Tang L. Histamine release and fibrinogen adsorption mediate 
acute inflammatory responses to biomaterial implants in humans. J Transl Med. 
2007;5:31. 
[58] Tang L, Jennings TA, Eaton JW. Mast cells mediate acute inflammatory responses 
to implanted biomaterials. Proc Natl Acad Sci U S A. 1998;95:8841-6. 
14 
 
[59] Thevenot PT, Baker DW, Weng H, Sun M-W, Tang L. The pivotal role of fibrocytes 
and mast cells in mediating fibrotic reactions to biomaterials. Biomaterials. 
2011;32:8394-403. 
[60] Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets 
for inflammatory diseases. Eur J Pharmacol. 2006;533:327-40. 
[61] Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib 
(AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE. 
2009;4:e7258. 
[62] Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, et al. Masitinib for 
the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. 
Am J Hematol. 2010;85:921-5. 
[63] Savage DG, Antman KH. Imatinib Mesylate — A New Oral Targeted Therapy. N 
Engl J Med. 2002;346:683-93. 
[64] Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. 
Imatinib mesylate reduces production of extracellular matrix and prevents development 
of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311-22. 
[65] Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nat 
Rev Immunol. 2006;6:218-30. 
[66] Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, et al. Masitinib as an 
adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-
controlled phase 2 trial. Alzheimers Res Ther. 2011;3:16. 
[67] Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, et al. Safety and 
activity of masitinib in combination with gemcitabine in patients with advanced pancreatic 
cancer. Cancer Chemother Pharmacol. 2010;66:395-403. 
[68] Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, et al. Phase II study 
of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic 
gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010;46:1344-51. 
[69] Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, et al. Masitinib in 
the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-







ADDRESSING MEDICAL DEVICE CHALLENGES WITH 
DRUG/DEVICE COMBINATIONS 
 








Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, 
















Keywords:  medical device, drug delivery, blood coagulation, foreign body 
response, infection, fibrosis, implant complications, local therapy 
 
 
Reprinted with permission from: Drug-Device Combinations for Chronic Diseases.  
New York: Jon Wiley & Sons; 2013. 
 
 16 
2.1  Introduction 
Implanted medical devices (IMDs) comprising synthetic biomaterials have seen 
exponential growth in their applications and clinical use over the past five decades 1. The 
scope and fields of use for IMDs have increased multiple-fold with the advent of new 
technologies, innovation and improved understanding of human physiology and its 
underlying problems.  Increasing rates of medical device adoption can be attributed to 
various factors, including aging median populations worldwide,2 innovations in design 
and function that increase performance and reliability, rising standards of living among 
patients in developing nations and noted improvements in patient quality of life offered 
by the devices.  New IMDs continue to offer improved treatment alternatives for 
cardiovascular, orthopedic, oncologic, and many other diseases 3. Given these factors, 
the global medical device market is expected to continue growing, reaching 
approximately US $302 billion in 2017 with an annual growth rate of ~6% over the next 
six years (2011-2017) 4. Tens of millions of people in the United States alone have some 
kind of IMD in their body. Despite enhanced safety and efficacy, new device design 
strategies are required to understand and address complex human factors affecting 
device performance in vivo. Innovations in design, biomaterials, surface modifications 
and biocompatible coatings, and device-based on-board drug delivery mechanisms are 
among strategies employed to improve clinical IMD performance. 
Drug-device combination medical products are innovative biomedical implants 
with enhancements to device function provided by the on-board formulation and local 
pharmacology of selected drugs at the implant site 5. Combination devices couple a drug 
loading and releasing mechanism onto an approved prosthetic implant. Together, these 
seek to provide several improvements to the in vivo performance and lifetime of 
implantable medical devices in various classes and capacities, including cardiovascular, 
ophthalmic, orthopedic, diabetes and cancer applications. Drug-device combination 
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products represent relatively new device class among implantable medical devices, one 
that is drawing increasing attention from both the pharmaceutical and device 
manufacturing industries as well as clinicians to address several long-standing problems 
associated with IMDs. In 2003, the Food and Drug Administration (FDA) approved a 
coronary drug-eluting stent (Cordis CYPHERTM, Johnson and Johnson, USA) opening 
the market to similar officially designated “drug-device combination products” in the 
United States 6. Several notable medical devices with locally delivered drugs had earlier 
precedent, namely steroid-releasing pacemaker leads, hormone-releasing intrauterine 
devices, antibiotic-impregnated catheters, aerosolized drug inhalers, drug-infused 
condoms, and several other precedents.   Additionally, several combination products 
also existed earlier in Europe than elsewhere, e.g., antibiotic-releasing bone cements, 
drug-eluting stents, heparin-coated catheters, and others (approved with the CE mark).  
FDA’s Office of Combination Products (OCP) was established in 2002 to provide a 
pathway for assigning principal FDA oversite and review policies for drug/biologic/device 
combinations that could otherwise be confused or compromised by traditional FDA 
review file assignments 7.  The objective was to provide a streamlined and consistent 
process for assigning these new products to FDA Centers based on claimed primary 
modes of action (i.e., device or drug). The OCP defines a “combination device” under 21 
CFR 3.2(e) as “A product comprised of two or more regulated components, i.e., 
drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, 
chemically, or otherwise combined or mixed and produced as a single entity; or two or 
more separate products packaged together in a single package or as a unit and 
comprised of drug and device products, device and biological products, or biological and 
drug products”.  Table 2.1 summarizes this classification system.  Most combination 
devices add a drug bioactivity adjunct to an already-approved implanted device to 
counteract challenges faced by the device in the context of the local host tissue 
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environment.  This can include inflammation, fibrosis, coagulation, and infection, 
improving performance in several conditions. One prominent example is the use of the 
drug-eluting stent, where local release of micrograms of drug to the vascular bed has 
reduced the need for surgical intervention by 40-70% over bare metal stents 8-10. 
However, combination products are often optimized into an integrated system from 
separate drug and device products: they were never designed de novo to complement 
each other in structure and function, i.e., controlled drug delivery often is an add-on 
feature to an existing FDA-approved medical device design that is sub-optimally adapted 
to the structural, mechanical or electronic function of the device 6. New strategies and 
new technologies that combine drugs, devices and biologics de novo as coordinated, 
unified new designs are expected to provide a new generation of combination products, 
more intelligently incorporating and merging new technologies, changes and refinements 
of both existing drug delivery mechanisms and medical device functions, shifts from 
traditional devices and drugs, while remaining compliant with regulations 6.  
Diverse classes of drugs are used in combination devices to enhance medical 
device and implant performance. Anti-inflammatory, antifibrotic, antiproliferative, 
antithrombotic and antibiotic drugs are primary classes of pharmaceutical agents often 
combined with a controlled delivery mechanism suited to the application. Site-specific 
and implant-specific drug interventions before, during and after medical device 
implantation can be used to alleviate several adverse host responses, providing a local 
therapeutic strategy when device design or systemic drug delivery alone are insufficient. 
For example, anticoagulants are applied to cardiovascular and intravascular implants to 
reduce device-based thrombosis, while antifibrotic, anti-inflammatory and 
antiproliferative drugs are used for soft tissue implants and endovascular stents 
susceptible to fibrous tissue in-growth and smooth muscle proliferation. Antibiotics are 
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released from orthopedic implants, shunts and percutaneous and urinary catheters that 
exhibit high infection incidence. 
Conventional therapeutics are administered in different ways, including nasal, 
oral, parenteral (intravascular, intramuscular, subcutaneous and intra-peritoneal), 
topical, transdermal and other administrative routes 11. While systemic administration 
has its merits, local drug administration can in some cases provide comparable results 
with significantly lower doses of drugs while limiting the drug efficacy and toxicity to the 
tissue surrounding the implant site. Drugs are combined with delivery technologies to 
control rates and local dosing of therapeutics to tissue beds surrounding implanted 
devices.  Typically, drugs are released systematically from the device surface using 
impregnated resins, or rate-controlling polymer films.  Occasionally, drugs are eluted 
from the bulk device as in the case of antibiotic-loaded bone cement. Local drug release 
limits drug dosing to low quantities, reduces systemic toxicity, increases durations of 
release and limits the area of release to the tissue bed surrounding the implant 6. Local 
drug release mechanisms offer several advantages over conventional systemic drug 
administration.  An ideal drug delivery system with a combination device should provide 
continuous and effective drug doses to the site of implantation while also offering 
possibilities to continue drug release for prolonged periods 12. Rates and durations of 
drug delivery depend on several factors such as the implant size, local tissue physiology 
and morbidity, drug pharmacology and potency in therapy, duration and location of drug 
release, its kinetics, drug and local clearance and toxicity. 
Due to the widespread development and use of combination products, a 
comprehensive understanding of drug delivery mechanisms and device functional 
improvements in the drug’s presence is necessary to improve their efficacy and scope of 
medical applications.  Mechanisms involved in drug delivery should be exploited to 
better match release to the local needs of each specific combination product.  The major 
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challenges faced by IMDs in clinical applications are shown in Figure 2.1: 1) nonspecific 
host response/foreign body reaction; 2) device thrombosis, and 3) biomaterial-
associated infections.  These all share some interrelated failure mechanisms that may 
amplify tissue-site adverse reactions and host responses.  For example, the link 
between thrombosis and infection is increasingly identified to be synergistic, as is the 
relationship between the host foreign body response and implant-centered infection.  
These increasingly complex host response relationships can be difficult to solve using a 
single device design, or biomaterials-based approach alone.  Use of local pharmaceutics 
with the device provides options to exploit device strengths and also drug targeting 
against multiple challenges in the implant site.  The remainder of this chapter serves to 
describe combination device approaches in the context of the current medical device 
and implant challenges in host tissue sites. 
2.2 The Host Foreign Body Reaction 
The host’s acute and chronic foreign body response (FBR) remains an unsolved 
challenge for many IMDs.  As the implantation of almost every medical device creates a 
wound (e.g., knee arthroplasty, pacemaker), or local disturbance of a tissue bed (e.g., 
contact lens), a normal host tissue wounding response is spontaneously initiated.  This 
reaction is primarily an abnormal tissue healing response that alters normal wound site 
healing in the presence of a foreign body (IMD), yielding a chronic unresolved tissue 
response, often resulting in excessive fibrosis. Extending the functional clinical lifetime of 
IMDs while reducing their adverse events in vivo remains an important goal.  
Nonetheless, despite many device improvements and design changes, this goal remains 
elusive. For example the host’s acute and chronic FBR are well-known to limit the 
lifetime of implanted sensors (i.e., glucose real-time monitoring devices) 13-15. Lack of 
tissue mechanisms preclude rational implant improvements and other more direct 
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therapeutic approaches.  IMDs spontaneously adsorb a diverse array of plasma proteins 
within the first few seconds of implantation 16. Neither the types and amounts nor 
orientations of these proteins on the implant can be controlled in vivo, but despite many 
assertions otherwise, this might not have much significance to the final tissue reaction.  
Surface properties of the implanted biomaterial certainly govern aspects of protein 
adsorption, but exactly how this then modulates the host reaction to the implant is less 
certain.  Many biomaterials of distinctly different bulk chemical and surface composition 
result in very similar endpoints in vivo in soft tissue, encased by fibrous overgrowth and 
an avascular capsule.  The IMD as a foreign body destabilizes homeostasis and 
hemostasis in host tissue and results in a modified “healing response” that adversely 
affects both the implant’s performance and host tissue surrounding it. 
The FBR is a consequence of aborted wound healing and the complex interplay 
between the complement and coagulation cascades with the host immune system. The 
complement system comprises cascades of blood and cell surface proteins triggered by 
pathogens and other “foreign” substances, including implanted biomaterials 17.  Blood’s 
potent intrinsic and extrinsic protease cascades are triggered by procoagulant stimulus 
18. In both systems, procoagulant and complement proteins are zymogen proteases 
activated by the foreign body interacting with the precursor zymogens through proteolytic 
cleavage 19, and each acting to amplify host cell-signaling and cell-recruiting capacity. 
FBR results from continuous host exposure to combinations of specific (activating) and 
nonspecific (activating) proteins on the foreign body and their protease activation.  
Subsequent chemotaxis and reactions from host immune and inflammatory cells lead to 
unresolved chronic healing responses, sustained inflammation, recruitment of fibroblasts 
and fibrotic encapsulation, and foreign body giant cell presence as a terminal response 
to the implanted device.  In this dynamic wound site response, normal wound site acute 
cell infiltrates comprising neutrophils and other leukocytes, and later monocyte and 
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macrophage invasion, stimulate release of inflammatory cytokines like IL-6, TNF-alpha, 
IL-4 and IL-13 (i.e., from mast cells) to accelerate recruitment of inflammatory and 
immune cells to the site of implant 15.  In normal wounds these abate, but a foreign body 
provides continuous inflammatory stimulus for sustained, abnormal cell signaling.  
Fibroblasts then arrive at the implant site and mediate the formation of an avascular 
fibrous tissue via exuberant collagen production around the implant that can act as a 
physical barrier blocking access to essential components of the tissue surrounding the 
implants, an area of local hypoxia and poor perfusion to create an infection niche, and 
also a physical impediment of prosthetic motion if required (i.e., joint arthroplasty) or 
adjacent tissue-on-tissue motion (e.g., surgical adhesions) that are highly painful. 
Chronically, the excess connective tissue remodels into a dense fibrous capsule 
(fibrosis) that “walls off” the implant, separating the IMD from its physiological 
surroundings. This foreign body capsule is the hallmark of the FBR, and adversely 
affects the general performance of IMDs, limiting their reliability and long-term success. 
Reactions of both the host on the implant and the implant on the host/blood/tissue need 
to be understood to enhance IMD performance. Figure 2.2 illustrates the sequence of 
host-materials events following the implantation of a biomaterial/ medical device into 
host tissue. 
While some implants remain unaffected functionally by the FBR, certain types of 
IMDs are highly compromised.  In particular, sensor implants like continuous glucose 
monitoring (CGM) sensors 20-22, pacemaker electrical leads 23, and neural deep brain 
stimulation arrays 24 undergo fibrosis that hinders function. The avascular fibrous tissue 
surrounding the implant impedes the implant’s electrical 25 and chemical contact with the 
surrounding tissue while also depriving it of essential analytes 26-28 and nutrients, 
rendering implants less efficient. Pacemaker leads underwent early drug modification, 
with steroid reservoirs and elution from their porous electrode tips enhancing their 
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impedance and conductance properties with tissue and their functioning lifetime, 
enhancing battery life and reducing fibrous tissue encapsulation 29,30. Many CGM 
sensors are placed subcutaneously where normal sensor fouling, including protein 
adsorption on or infiltrated into the implanted sensors, as well as inflammatory wound-
site cellular reactions eventually limit analyte diffusion (mostly glucose and oxygen) into 
the sensing element, and contribute to the observed continual decreased analyte 
sensitivity with prolonged implantation 14,21,31.  In addition to ubiquitous sensor fouling 
and encapsulation, the host’s acute inflammatory response to the implanted foreign body 
produces an immediate, sustained cascade of local tissue cellular reactions that alter the 
local environment around the implant, substantially modifying local metabolism and 
homeostasis.  This triggers a departure from normal tissue analyte levels and causes the 
sensors to produce highly altered analyte levels from acute inflammation -- an acute 
reporting phenomenon called “break-in” 32. 
As the host foreign body response in soft and hard tissue sites typically produces 
device-based challenges associated with excess or unresolved inflammation, fibrosis, 
and infection, combination device strategies seeking to address this issue have used 
drugs with known pharmacological actions against these specific problems.   
2.2.1 Anti-inflammatory drug candidates to inhibit the foreign body 
response 
Anti-inflammatory steroidal drugs (e.g., dexamethasone) are clinically familiar 
and used to reduce inflammation and the host FBR in tissues surrounding implant sites 
33,34. Dexamethasone, a glucocorticoid agonist, crosses cell membranes and binds to 
glucocorticoid receptors controlling different inflammatory pathways with high affinity by 
inhibiting leukocyte infiltration at sites of inflammation, suppressing humoral immune 
responses, and reducing edema and scar tissue. Molecular basis for dexamethasone’s 
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anti-inflammatory actions are thought to involve the inhibition of cyclo-oxygenase 
enzyme 35 that regulates arachidonic acid metabolism responsible for production of 
inflammatory prostaglandins. 
Local controlled-release systems containing the steroid, dexamethasone, have 
been used in intraocular application post-surgery in cataract treatments 36-40. Local 
dexamethasone release 41 has also been used to reduce neointimal formation in the 
arterial wall after balloon angioplasty 42,43, and to prevent restenosis in intravascular 
drug-eluting stents 44. Dexamethasone has also been used for improve the performance 
of pacemaker leads 45. Dexamethasone release from PLGA microspheres coated onto a 
cotton suture implant has shown to decrease the acute inflammatory reaction around the 
implanted suture material 46. Dexamethasone has been used in combination with 
angiogenesis factors like vascular endothelial growth factor (VEGF) to promote new 
blood vessel growth while reducing inflammation in the tissue surrounding a hydrogel 
(PVA) scaffold implant 47. Sequential or simultaneous release of dexamethasone and 
VEGF has been shown to improve the performance of implanted biosensors 47-51.  
2.2.2 Antiproliferative drug candidates to inhibit the foreign body 
response 
Sirolimus, also called rapamycin, is a potent immune-suppressive drug used in 
combination with medical devices. As a potent inhibitor of cytokine and growth factor-
mediated cell proliferation. sirolimus acts by inhibiting activation of the intracellular 
protein enzyme, mTOR (mammalian target of rapamycin) 52, a downstream mediator of 
the PI3K/Akt phosphorylation signaling pathway regulating several key cell functions. 
Receptor-based inhibition of mTOR results in the blockage of cell-cycle proliferation in 
the late G1 to S phase, causing antiproliferative and antihyperplastic actions 53,54. Over 
70 related “limus” derivatives are known drug candidates.  Everolimus, temsirolimus, 
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deforolimus, tacrolimus, and ABT-578 are also used as potent antiproliferative drugs. 
Paclitaxel is another commonly used antiproliferative drug used with medical devices 
such as drug-eluting stents. Paclitaxel inhibits cell proliferation, cell motility, shape and 
transport between organelles 55.  Both rapamycin and paclitaxel have substantial clinical 
records as approved therapeutics for a number of indications independent of devices.  
2.3 Device-based Thrombosis 
Under normal, steady-state circulation conditions (hemostasis), blood 
continuously contacts host endothelium with an intrinsic, active anticoagulant and 
antithrombotic system. Injury to blood vessels exposes subendothelial components, 
releases pro-coagulant stimulants and disrupts hemostasis. Natural host response to 
this disruption involves blood platelet adhesion, activation, and aggregation in 
combination with activation of intrinsic, extrinsic coagulation cascades terminating in the 
formation of a crosslinked fibrin clot.  These natural coagulation cascades are depicted 
in Figure 2.2.  The combination of platelet and procoagulant cascade activation rapidly 
produces a thrombus/clot that stabilizes the injury and prevents further blood loss. 
Thrombus formation plays an important role in the maintenance of hemostasis. 
Thrombin-mediated fibrin polymer traps and stabilizes clusters of activated platelets to 
yield a stable thrombus critical for survival and also contributing powerfully to local 
wound healing. 
Endothelial cells (ECs) lining the walls of the endothelium continuously 
synthesize and regulate several key molecules necessary for the maintenance of host 
hemostasis and the intrinsic blood compatibility of vasculature. The EC surface is a 
dense, brush-like layer of hydrated proteoglycans, called the glycocalyx. Glycocalyx 
glycoproteins enzyme-grafted with glycosaminoglycans (GAG) side chains 56 including 
heparan, dextran and chondroitin sulfate proteoglycans, and hyaluronic acid, are 
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negatively charged and highly hydrated, acting as a barrier and a lubricant between the 
ECs and blood components 57. ECs also actively produce and release nitric oxide and 
prostacyclin (PGI2) that actively prevent platelet adhesion and activation 58,59. Heparan 
sulfate proteoglycan synthesized by the ECs inhibits platelet adhesion and activation 60 
while also functioning as a catalytic cofactor for binding antithrombin-III and thrombin 
together to facilitate thrombin inhibition and anticoagulation 61,62. ECs also produce 
tissue-type plasminogen activator (t-PA) and urokinase that act to initiate fibrin 
degradation and aid in clot dissolution 63,64. This t-PA activity is tightly regulated by the 
EC-produced plasminogen activator inhibitor type-I 65-67. 
Cardiovascular medical devices are placed into contact with patient’s blood for 
varying periods of time, ranging from minutes (e.g., vascular access devices) to many 
hours (blood pumps, dialysis filters, central lines), to years (e.g., stents, heart valves, 
vascular grafts, pacemaker leads). The blood-contacting surfaces on these devices are 
critical to their performance, seeking to minimize activation of both platelets and the 
coagulation cascades. However, no materials chemistry or coatings used on these 
devices have proven clinically reliable in limiting risks of device-based thrombosis to 
date.  Some blood-contacting biomaterials are grafted with heparin-like coatings, or 
polymers mimicking the EC glycocalyx68.  Figure 2.3 shows one example of this device-
based surface modification approach using heparin.  Other approaches are designed to 
release anticoagulant and antiplatelet drugs for short durations69. No materials yet 
provide all the passive, active and functional aspects of ECs in maintaining hemostasis, 
and therefore all induce thrombosis in contact with blood to varying degrees.  Device-
induced thrombosis is a major cause of failure in blood-contacting biomaterials, mainly 
cardiovascular implants – that constitute a major class of chronic disease-related IMDs.  
Implantation of a medical device lacking the properties of a healthy endothelium 
constitutes the introduction of a foreign object into circulation. Blood-material interactions 
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after implantation spontaneously and immediately trigger a series of complex reactions 
involving protein and platelet absorption on the biomaterial surface, formation of clots 
and emboli, and activation of the host’s immune system. 
2.3.1 Platelet activation in device-based thrombosis 
Platelets are anuclear cytoplasmic fragments present in blood essential for rapid, 
reliable blood clotting and wound healing 70. Platelets play an essential role in controlling 
blood loss and maintain hemostasis. One common platelet mode of action is the 
formation of a stable platelet plug when the blood vessel wall is damaged and the 
endothelial cell layer is disrupted, exposing the underlying basement membrane and 
extracellular matrix. With every surgical device implantation, blood vessels in the tissue 
surrounding an implant are injured, exposing collagen IV in the subendothelial layers to 
blood which results in the activation of circulating platelets. Additionally, platelets also 
get activated when they undergo shear stress caused by flow disturbances common to 
implanted devices. Platelet activation is followed by platelet degranulation, then 
aggregation and adhesion to each other and to the implanted material.  Degranulation 
serves to release a broad array of potent platelet-derived biochemicals that potentiate 
local thrombosis by accelerating both local coagulation cascade reactions and platelet 
activation by release of highly procoagulant stimulants, enzyme substrates and co-
factors. The aggregated platelets are stabilized into a thrombus/clot by the newly formed 
fibrin polymer. Circulating platelets get activated under three major circumstances: a) by 
contacting the basal lamina of the endothelial vessel wall, b) by contact with a 
biomaterial surface, and c) due to flow disturbances caused in the presence of a 
biomaterial. Platelet adhesion, activation and aggregation is combined with simultaneous 
thrombin-mediated fibrin polymerization that together result in thrombus formation. 
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2.3.2 Extrinsic and intrinsic coagulation cascades 
A biomaterial surface exposed to blood is coated with thousands of plasma 
proteins within seconds 71. This adsorption activates some plasma proteins by inducing 
conformational changes or cleaving small fragments that trigger coagulation and 
inflammatory responses to the implanted device 72-74. The coagulation cascade 
comprises two main branches:  the intrinsic pathway (activated by contact with a 
biomaterial surface) and the extrinsic pathway (induced by EC injury). Both pathways 
converge at the proteolytic formation of thrombin from its prothrombin zymogen, the 
penultimate cascade step to converting soluble plasma and platelet-derived fibrinogen to 
fibrin polymer. Fibrin polymer is a major protein component of the natural clot. Activation 
of intrinsic and extrinsic proteolytic reactions following blood contact with biomaterials 
actively and consistently produces thrombin-mediated fibrin clots unless 
pharmacological treatments attenuate these natural responses, typically by inhibiting key 
enzymes. The series of coagulant events triggered by the activation of intrinsic or 
extrinsic pathways following the implantation of a medical device into blood are shown in 
Figure 2.3. Adherent platelets – both on the biomaterial as well as trapped by the clot – 
activate to release numerous potent thrombotic promoters and catalysts by 
degranulation. They also recruit more circulating platelets to the device surface.  
Subsequent device-based thrombosis and thromboemboli formation produce many 
clinical complications, causing failure in small-diameter grafts, stents, valves, pumps, 
catheters and other cardiovascular implants.  Furthermore, causal links between device 
thrombosis and device-centered infection are increasing.  
2.3.3 Biomaterials-associated infection  
All implantable devices – from short-term devices like contact lens, glucose 
sensors, urinary catheters, endotracheal tubes, to long-term surgically implanted devices 
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like pacemakers, cardiac valves, endothelial grafts, orthopedic implants, suffer 
commonly from varying risks of biomaterials-associated infections (BAIs), or implant-
associated infections 41. BAIs remain a major cause of IMD failure despite years of 
device innovation, improved quality of care and surgical techniques 75. In the United 
States, approximately 2 million nosocomial infections costing $11 billion occur annually 
76. A majority of nosocomial infections (60-70%) are biomaterial-associated infections 
caused from the increasing use of urinary and, venous catheters, orthopedic implants, 
shunts and other implants, 77 and involving significant mortality and economic costs. 
Infection mitigation is a common problem with IMDs and a primary focus of surgical 
antibiotic prophylaxis in device placement. BAIs most often result from bacterial 
contamination of implants intra-operatively during the implantation procedure.  They are 
able to colonize implants using the implant-adherent protein layer and thrombus, 
proliferating at rates that outpace host wound healing.  Bacterial adhesion leading to the 
formation of mature biofilms on the surface of a biomaterial is shown in Figure 2.4. 
Bacteria and other pathogens have multiple sources during surgery: no surgical suites, 
surgical personnel or patients are sterile, Pathogen seeding of implants and surgical 
sites is likely, yet only small fractions of implants actually colonize and lead to clinically 
symptomatic infections as BAIs.  Nonetheless, BAIs can result in difficult-to-treat 
systemic infections with costly adverse complications and mortality. BAIs are most 
prevalent in orthopedic 78,79, dental 80, cardiovascular 81-83, neural and ophthalmological 
implants 84,85 and involve a broad spectrum of pathogens, many in polymicrobial implant 
infections.  Rates of infection at the site of implantation post-surgery increase with the 
severity of the vascular and tissue injury 86.  Upon detection, BAIs often fail systemic 
administration of antibiotics.  Therefore, common treatment most often involves 
immediate implant removal followed by long-term parenteral administration of antibiotics 
and then replacement with a second new implant.  This often comes with associated 
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morbidity and high treatment costs.  Little change in BAI incidence has resulted from 
changes in surgical practice, device design, or antibiotic usage, prompting re-
examination of the entire medical device infection scenario 87. Since systemic antibiotic 
therapies have failed to bring down implant infection rates, local release antiseptics and 
antibiotics has been sought in combination device form. 
2.4 Combination Medical Devices 
2.4.1  Drug-eluting stents 
Coronary stent restenosis has been a major challenge since the introduction of 
percutaneous coronary intervention for coronary artery disease 88. Use of rigid but 
flexible endovascular scaffolds such as stents prevents the recoil and collapse of the 
vessel while also mitigating the vessel restenosis experienced after balloon angioplasty 
89,90. Although development and use of stents in percutaneous coronary interventions 
(PCI) has demonstrated improvements over balloon angioplasty, vessel restenosis or in-
stent restenosis after bare metal stent deployment also poses challenges to successful 
PCIs, resulting in past patient re-interventions in up to 50% in several patient classes 
depending on stent placement and patient pathophysiology 91,92. Systemic administration 
of drugs to reduce in-stent restenosis is ineffective 93-95 mainly due to poor drug 
bioavailability, toxicity and insufficient drug dosing to the implant site.  Popularity of drug-
eluting stent (DES) is due to proven success in mitigating the effects of tissue 
hyperplasia-caused vessel occlusion 9,96,97. DES use has reduced the occurrence of 
repeated PCIs and surgical revascularization procedures to treat restenosis by 40% to 
70% 8-10. Emerging classes of DES coated with bioactive agents (DNA, proteins and viral 
vectors) and biopharmaceuticals provide improved safety and efficacy in certain cases 
but also pose challenges during their fabrication and require specific formulations and 
delivery mechanisms for reliability and efficacy 98. 
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In coronary applications, DES devices are typically localized expandable, slotted 
metal tubes (~4mm long) coated with a polymer carrying a small dose (micrograms) of 
pharmacological agent.  DES are collapsed around a deployment catheter and installed 
at a coronary lesion vessel by catheter-initiated intraluminal expansion.  This provides 
structural support to the vessel while releasing drug locally to the vessel wall at the stent 
implant site 99.  The DES provides the advantage of effective localized drug delivery and 
therapeutic efficacy at the lesion site while avoiding excessive dose exposures through 
systemic delivery 100,101.  Other advantages include directional delivery of drug to the 
vessel wall tissue and only small fractions entering the blood stream.  Additional new 
stent designs can build drug depots in spatially designated locations on-stent 102, with 
versatility to carry multiple drugs, releasing with different release kinetics, and also two 
distinct therapeutic functions – antithrombosis on the blood side and antiproliferatives on 
the tissue side 103.  
Sirolimus-eluting stents originally were the pioneer DES, showing noticeable 
improvements over early bare metal stent designs in PCI procedures, reducing cell 
proliferation, migration and restenosis from the vessel bed at the stenting site. The 
sirolimus-eluting stent (Cordis CYPHERTM) was the first DES to receive clinical approval 
104,105 in Europe, and the first “official” combination device approved by the FDA in 2003. 
Sirolimus is now the most extensively studied drug to reduce in-stent neo-intimal 
hyperplasia following coronary stent deployment 106. Sirolimus-eluting and paclitaxel-
eluting stents (TAXUS®, Boston Scientific, USA) are the two commercially available, first-
generation DES. These are coated with a very thin (~µm) nondegradable polymer layer 
(e.g., polyisobutylene or polymethacrylate copolymers) containing very little drug within 
the coated polymer (~µg/mm length of stent), released with an early significant burst (up 
to 50%) within the first 24-36 hours postimplantation followed by slower release lasting 
more than 6 weeks in some cases 6.  
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After initial enthusiasm with the first-generation DES, controversial debate has 
ensued over long-term DES safety, with a shift in clinical focus to increased risks of late 
stent thrombosis 107,108. Although both CYPHER and TAXUS effectively achieved primary 
goals of reducing cellular restenosis across almost all lesion and patient subsets over 
bare metal stents, their safety has been limited by sub-optimal polymer biocompatibility, 
delayed stent endothelialization leading to late stent thrombosis, and local drug toxicity 
109-113. The permanent presence of the noneroding polymer covering the stent struts and 
wires has been correlated with tissue inflammatory response and local toxicity in 
preclinical studies 114,115. Stent thrombosis risk gained primary focus after the dominant 
restenosis issue had been resolved using drug-eluting stents: DES are comparable to 
bare metal stents in occurrence of stent-associated thrombosis 116. This has prompted 
new technologies and designs to overcome the thrombosis problem using new stent 
designs, stents with multiple drug reservoirs containing both antithrombotics and anti-
proliferatives, absorbable or biodegradable polymers, nonpolymer drug-loaded surfaces 
and changes in the types and doses of currently used antiproliferative drugs placed on-
stent. 
Recent clinical introduction of the biodegradable polymer-coated DES 117 seeks 
to overcome stent thrombosis attributed to the permanent polymer layer on first 
generation DES. Biodegradable stent coatings have been designed to release loaded 
drug for an intended amount of time before completely degrading. Clinically familiar 
poly(L-lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA) and poly(D,L-lactide) 
(PDLLA) remain popular choices for biodegradable polymer DES coatings. BioMatrix 
(Biosensors Inc, USA) is a stainless steel stent containing Biolimus A9 (a derivative of 
sirolimus) as drug on the abluminal surface facing the vessel wall targeting the mTOR 
protein, loaded in a PLA coating. The drug is released to the vessel wall over 2 to 4 
weeks and the PLA coating is gradually absorbed between 6 and 9 months.  Several 
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other novel DES with biodegradable coatings are in development. Cardiomind 
(Cardiomind Inc., USA), ELIXIR-DES (Elixir Medical Corporation, USA), JACTAX 
(Boston Scientific Corporation, USA) and NEVO (Cordis, USA) are example stents in 
development and clinical trials with degradable coatings used to deliver anti-proliferative 
drugs to mitigate neointimal tissue hyperplasia in PCI procedures.  
As the model and precedent combination product approved by the FDA, DES are 
an excellent example of combining a drug with a device to target and address a specific 
problem unsolved by either component alone or used together but separately. Despite 
improvements in early prototypes and first-generation stents using new designs, 
materials, drugs, drug loading methods, drug release kinetics, release duration and 
improved understanding of local pharmacology and complications arising several 
months to years after DES placement, new technology should better address newer 
DES problems associated with late stent thrombosis, endothelialization and local drug 
toxicity.  Additionally, expansion of DES use to other challenging luminal lesions, both in 
vasculature, gut/digestive, and reproductive tissues will require further innovation of 
drugs on devices. 
2.4.2  Antimicrobial central venous catheters 
Central venous catheters are a critical component for fluid delivery and retrieval, 
parenteral drug and nutritional fluid administration in a variety of clinical settings for 
critically ill patients. In the United States, physicians insert more than 5 million central 
venous catheters every year 118. The two major complications associated with catheters 
are bacteremia (infection) and thrombosis 119. Catheters coated with both antimicrobial 
and antithrombotic agents have been developed and commercialized.  Antimicrobial-
coated catheter use and efficacy have been studied for more than a decade 120. 
Infections associated with catheters are classified as catheter-related blood-
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stream infections (CRBSI). CRBSI can occur in 3-10% of all patients using central 
venous catheters 121, affecting over 300,000 patients in the United States annually 122 
and causing more than 25,000 patient deaths 123,124. Systemic administration of 
antibiotics to treat CRBSI either prophylactically or therapeutically is not a clinically 
preferred nor reliably efficacious route. Local administration of antimicrobial agents from 
properly designed combination devices seeks to provide small efficacious doses of 
therapeutics released into local tissue sites without requiring high systemic drug dosing.  
Techniques developed to reduce CRBSI incidence include modified catheter 
designs, use of antimicrobial impregnated catheters, use of cuffed tunneled catheters, 
local topical treatments, and use of antimicrobial lock solutions 125. Coating or 
impregnating the surface of central venous catheters with antimicrobial agents helped to 
markedly reduce the risk of CRBSI, and their use has now become the standard of care 
126,127. Antimicrobial-coated catheters employ different methods to immobilize the 
antimicrobial agents onto catheter surfaces – both luminal and external. One method is 
to simply add the antimicrobial agent to the precursor polymer granules used to fabricate 
the catheter, similar to adding other constituents like pigmentation or stabilization 
compounds prior to injection molding 128. Another procedure involves electrostatically 
coating catheter surfaces layer-by-layer with antimicrobial agents and a binding material 
with opposite electrostatic charge.  Hydrophobic alkylated regions of cationic surfactants 
like tridodecylmethylammonium chloride (TDMAC) have been adsorbed on catheter 
surfaces, presenting a cationic surface to anionic drug molecules binding to the 
surfactant-coated surface 129,130.  Recently, a zwitterionic polymer brush grafted layer has 
shown preclinical efficacy as an antimicrobial coating 131,132. Addition of active drug 
release capability to this layer would provide enhanced bioactivity.  
These strategies facilitate incorporation of different antimicrobials onto catheter 
surfaces to reduce CRBSI. Multiple antimicrobial agents are preferred (typically 
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combinations of an antiseptic and antibiotic agent) to reduce the development of 
antimicrobial resistance to any single agent 133. According to Centers for Disease Control 
and Prevention (CDC) guidelines, catheters containing combinations of 
minocycline/rifampin (MR) antibiotics, and combinations of chlorhexidine/silver 
sulfadiazine (CS) antiseptics are the two most effective antimicrobial catheters to treat 
CRBSI 126,127.  Catheters coated with both antibiotics and antiseptics are FDA and CE 
approved and commercialized (e.g., CS: ARROWgard®, Arrow international, USA; MR: 
Cook Specturm® series catheters, Cook Critical Care, USA). Both ARROWgard® and 
Spectrum® series catheters have antimicrobial agents impregnated on internal and 
external surfaces using TDMAC adlayers 134. Both MR and CS have shown broad-
spectrum antimicrobial activity to both Gram negative and Gram positive organisms and 
fungi. Several randomized trials 135,136 conducted with MR and CS showed superior 
performance from MR-impregnated catheters versus CS-impregnated catheters in 
preventing CRBSI specially in patients needing catheter-based access for more than 7 
days up to 50 days in situ 137. Catheters impregnated with MR have been shown to 
exhibit higher anti-adherence activity and prolonged antimicrobial durability compared to 
catheters with CS against vancomycin-resistant Staphylococcus aureus and multidrug-
resistant (MDR) Gram negative organisms other than Pseudomonas 138. Although MR 
shows high antimicrobial activity against staphylococci and most of the Gram negative 
bacilli 138, they are less effective against Pseudomonas aeruginosa (contributing 3 to 5% 
of CRBSI) and Candida species (contributing about 12% of CRBSI) 138. In vitro studies 
using catheters coated with a combination of MR and CS have shown to be effective 
against vancomycin-resistant Staphylococcus aureus, Gram negative bacilli, 
Pseudomonas aeruginosa and Candida species 139. 
Silver nanoparticle-impregnated catheters (SNP: Medex Logicath AgTive®, Smith 
Medical International Ltd, UK) are CE-approved and commercially available in Europe. 
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Catheters coated with silver-based zeolite (SZ) on blood-contacting surfaces (e.g., 
Lifecath PICC Expert with AgIONTM from Vygon international in Europe) use controlled 
release of silver nanoparticles from the coating to provide antimicrobial properties to the 
catheter. In a recent study 140 conducted over 14 months involving 246 central venous 
catheter insertions (122 silver zeolite-impregnated and 124 nonimpregnated catheters), 
the AgIONTM catheters showed reduced CRBSI compared to uncoated catheters. In 
silver nanoparticle-impregnated catheters, a recent study has shown that platelets 
colliding with silver nanoparticles exposed on the coating surface accelerate the process 
of catheter-related thrombosis while simultaneously exhibiting strong antimicrobial 
properties 141. 
Catheters with antithrombotic coatings are used to reduce the incidence of 
coagulation. The Carmeda® BioActive Surface (CBAS) on Spire Biomedical® catheter 
products (Spire Biomedical, Inc., Bedford, MA) and the Trillium® Biosurface developed 
by BioInteractions Ltd. (UK) are two commercially available antithrombotic-coated 
catheters. Both catheters use heparin-bonded polymer surfaces as an anticoagulant 
interface. Heparin is a polysaccharide with anticoagulant properties and has been used 
as an antithrombotic agent for clinical applications 142. The CBAS treatment consists of 
heparin molecules covalently bonded to the catheter surface, exposing active heparin 
sequences to bind ATIII and thrombin from the bloodstream while shedding other protein 
components.  Schematic representation of thrombin inhibition on a bioactive heparin-
coated surface to limit device-based thrombosis is presented in Figure 2.5. The Trillium® 
Biosurface treatment combines a hydrophilic polyethylene oxide layer with negatively 
charged sulfate polymers to retain hydration at the catheter surface and reduce blood 
adsorption. In addition, it has heparin covalently bonded to the polyethylene oxide layer 
for anticoagulation 143. Although catheters coated with active antithrombotic layers are 
clinically used, the effects of these coatings on catheter complications are yet to be 
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evaluated in the hemodialysis population where these complications also exist.  
Importantly, many such technologies have not been shown to produce significant cost-
benefit using placebo-controlled blinded prospective studies. 
Catheter lock solution (CLS) is another strategy used to reduce CRBSI incidence 
from central venous catheters. A biocompatible solution containing a combination of 
antimicrobial and anticoagulant agents constitutes the CLS. The CLS is injected into the 
lumen of the catheter after a hemodialysis session and retained there to reduce 
incidence of thrombus and associated biofilm formation. Catheter thrombosis can be 
limited using heparin solutions or treated by infusing a thrombolytic agent such as 
urokinase or tissue plasminogen activator [tPA] into the lumen of the catheter 144,145. In a 
recent study, athrombogenic CamouflageTM-coated (artificial glycocalyx) catheters have 
exhibited reduced need for urokinase injections for successful catheter tap and blood 
drawing over uncoated catheters in cancer patients with long-term catheters 68. 
2.4.3 Antimicrobial urinary catheters 
Urinary catheters allow passage of urine for treatment for patients with urinary 
retention, general surgery recovery, bladder obstruction, paralysis or loss of sensation in 
the perineal area 6. Urinary catheters are generally used to manage urinary incontinence 
in elderly patients or in patients with long-term spinal cord injuries. More than 30 million 
urinary catheters are employed in patients annually 146.  Unfortunately, catheter-
associated urinary tract infections (CUTI) remain the most common nosocomial infection 
147. Catheter surfaces in contact with the urethral epithelia facilitate bacterial 
contamination, adhesion, retention, and biofilm formation on both the abluminal and 
luminal surfaces eventually leading to infection of the urethra, then the bladder, and 
ascending into the ureters unless the catheter is exchanged frequently 148. Microbes in 
the catheter mediate the breakdown of urea, resulting in an increase in the urine pH, 149 
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inducing formation of mineral crystals on the catheter surface, leading to the formation of 
urinary infection stones 149 and blockage of the lumen by encrustation, which can 
produce kidney and blood stream infections.  
Systemic antibiotic therapies, antimicrobial topical ointments, and the use of 
antimicrobial agents in collection bags are commonly used to treat CUTIs. Silver-
impregnated urinary catheters claim 30% reduction in the incidence of CUTI in some 
studies although this is not a consensus 150. Several catheters based on silver and silver 
oxide coatings are commercially available in the United States (SilvaGard®, (I-
Flow/Acrymed), KENDALL DOVER® series catheters (Tyco Healthcare), BACTI-
GUARD® silver (C.R. Bard)) 75. A recent UK study involving patients with urethral 
catheterization for up to 14 days found that silver-coated catheters were ineffective 
against infection; the incidence of infection is comparable to uncoated PTFE 
catheters151.  
Ciprofloxacin, gentamicin, norflaxin, nitrofurazone, and combinations of 
compounds, such as chlorhexidine and protamine sulfate have been successfully 
incorporated into catheter coatings 152. Nitrofurazone-coated catheters (Rochester 
Medical, MN) are an emerging class of antimicrobial urinary catheters shown to be 
efficacious against E. coli 153 and have exhibited better antimicrobial properties than 
silver-treated catheters 154 in in vitro studies. However, further prospective double-blind 
powered two-arm clinical studies are required to validate claims for the efficacy of silver-
coated and nitrofurazone-coated catheters in CUTIs. 
2.4.4  Orthopedic drug-eluting implants 
Bone defects from trauma, disease, surgical intervention and congenital 
deficiencies are among the most challenging orthopedic repair problems faced worldwide. 
Autologous bone grafts are the gold standard to treat bone defects but are limited, not 
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always appropriate, with harvesting complications, including infection susceptibility. Bone 
fractures and joint deficiencies are increasingly treated using a variety of implanted 
biomaterial stabilization devices including bone cement, hip, knee, shoulder and elbow 
prosthesis, plates, nails, rods, wires, pins, and screws. Projected market revenues for 
such orthopedic implants are estimated at $23 billion in 2012 155. Bone-implant bonding 
156 and long-term stabilization pose significant clinical challenges including implant 
infection, bone resorption and implant loosening 157-159. Despite use of advanced 
stabilization mechanisms and implant instrumentation, some fractures are slow-healing or 
nonunions, requiring revision surgeries at significant expense and patient morbidity. 
Recent advances in drug delivery are increasingly used with orthopedic implants as 
combination devices 160. Increasing reports document effects from delivery of small 
molecule osteoinductive agents (drug 161, scaffold 162, gene and cellular delivery 163,164, 
biologically derived growth factors, anti-osteoporotic agents, and osteo-synthetic genetic 
materials like DNA transgenes and siRNA to bone defects from a variety of implant 
devices and vehicles 165-172.    
BAI remains a major concern in orthopedic implants 173. Rates of infection are 
estimated to be 1% for primary hip implants, 4% for knee implants (higher for secondary 
revisions), and more than 15% for some trauma-associated open fracture implants 155. 
Orthopedic implants carry a lifetime risk of infection (acute and hematogenous sources) 
and are clinically addressed in most cases by revision surgery involving a further 
substantial risk of infection 155.  A commonly used clinical approach to manage 
orthopedic implant infection is the use of antibiotics in bone cement, 
polymethylmethacrylate (PMMA) or PMMA beads. These nondegradable polymer 
cements have been used to prevent osteomyelitis for four decades 174-176 using either 
bulk impregnation by the aminoglycoside antibiotics, gentamicin or tobramycin 6,177, or 
vancomycin (Europe only).  The first antibiotic-blended bone cement to be approved in 
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the United States was Simplex P (Stryker Howmedica Osteonics) containing tobramycin 
6. The Palacos™ series of bone cements from Biomet, Inc. (Warsaw, USA) contain 
gentamycin and have been approved shortly after Simplex P. Recently, Depuy 1 
gentamycin-releasing bone cement (Depuy Orthopaedics) has been FDA-approved. In 
vivo studies have demonstrated the efficacy of antibiotic-loaded cements in reducing 
orthopedic implant infections within a short time after implantation 178-180. However, 
despite wide enthusiasm, drawbacks limit clinical applications of antibiotic-loaded bone 
cements. Pharmacokinetics studies show the inefficiencies of gentamicin release from 
antibiotic-loaded PMMA bone cements or PMMA beads, with less than 50% of the 
antibiotic release by 4 weeks 181-184. The primary concerns with the use of antibiotic-
loaded bone cements are possible allergic reactions to the antibiotic used, and the 
development of drug resistance to the antibiotic at the implant site. 
An antimicrobial tibial internal fixation nail coated with a degradable polymer 
containing gentamicin is marketed in Europe. The polymer coated over the metal nail 
covers the cannulation, enabling antibiotic delivery to the intramedullary canal and 
releasing antibiotic for ~2 weeks 185,186. The FDA recently approved a polyurethane 
sleeve coated with gentamicin (OrthoGuard AB, Smith & Nephew, UK) that can be used 
for coating pins and wires used for external fixation devices 187. 
2.4.5  Antimicrobial sutures 
According to the CDC, the overall incidence of surgical site infection is estimated 
to be 2.8% in the United States 188. Surgical sutures allow microbial adherence and 
colonization similar to other biomaterials 189 and contribute to surgical site infection 
incidence. Microbial colonization to suture materials is highly variable, dependent on 
specific microbial species, and suture structure, and chemical composition 190. Braided 
sutures have been shown to have higher microbial colonization compared to nylon-
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based monofilament sutures 191. Triclosan-coated braided polyglactin 910 suture (Vicryl 
Plus Ethicon, USA) has been developed to mitigate suture-induced surgical site 
infections. Several in vitro and in vivo studies 192,193 have shown that the triclosan-coated 
Vicryl Plus sutures effectively inhibit growth of normal and methicillin-resistant strains of 
S. aureus and S. epidermidis 192 while showing no difference in physical (strength, 
breaking force, etc.) and degradation characteristics compared to uncoated polyglactin 
910 sutures 193. Recent clinical trials have shown that use of triclosan-coated Vicryl Plus 
sutures in a diverse group of 450 patients resulted in a statistically significant reduction 
in the incidence of surgical site infection 194. However, some studies advise caution and 
the need for larger scale studies 195.  Silver-containing sutures are being developed by 
X-Static.  Another antimicrobial suture being developed by Polymedix (PolyCideTM) 
contains the antibiotic, polycide, which disrupts microbial cell 75. New antimicrobial 
strategies should be developed to overcome the limitations of current technologies. 
2.4.6  Vascular grafts with antithrombotic coatings  
Synthetic vascular grafts have been used to treat vessel occlusion caused by 
vascular disease for over four decades.  Large diameter grafts have substantially better 
success rates clinically than those below 5mm diameter, regardless of biomaterials 
used.  Small-diameter vascular graft failure generally occurs as a consequence of acute 
thrombus formation on the graft luminal surface, anastomotic intimal hyperplasia, or 
progression of vascular disease 196. Although anastomotic hyperplasia and disease 
progression are important factors for failure, reducing the propensity for acute thrombotic 
failure by improving graft surface blood compatibility has significant potential for 
improving clinical performance of small-diameter vascular grafts. Small-diameter 
expanded polytetrafluoroethylene (ePTFE) vascular grafts containing surface-
immobilized heparin are FDA-approved for treating vascular occlusion. CBAS-coated 
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vascular grafts (e.g., Gore® PROPATEN® Vascular Graft, Gore® VIABAHN® 
Endoprosthesis, W. L. Gore, USA) containing immobilized heparin on the graft luminal 
surface are commercialized.  Studies have shown reduction in thrombogenicity for small-
diameter ePTFE vascular grafts containing immobilized heparin compared to uncoated 
ePTFE grafts 197. 
2.4.7  Cerebrospinal shunts 
Hydrocephalus is treated using biomaterials-based cerebral shunt implants that 
drain excess cerebrospinal fluid (CSF) from the cranium to abdomen to relieve 
intracranial pressure 198. Infections remain a major clinical complication in using CSF 
shunt implants and usually require frequent replacement of the shunt system at 
substantial cost and morbidity (usually in infants and children) 199. Antibiotic-impregnated 
CSF shunts demonstrate clinical efficacy in reducing implant infections 200,201. 
BACTISEAL® from Depuy and ARES® from Medtronic are two antibiotic-impregnated 
CSF shunts that contain both clindamycin and rifampicin, released from the shunt 
surface. Both products demonstrate reduced infection against Gram positive bacteria for 
at least 31 days after implantation 202,203.   This area however still faces numerous 
challenges in producing a long-duration product that performs reliabiy and reduces shunt 
replacement frequency. 
2.5 Future Directions 
2.5.1 Orthopedic fixation plate sleeves 
New biodegradable polymer sleeves formulated with various therapeutics and 
readily mounted onto orthopedic plates and screw fixation implants intra-operatively prior 
to implantation provide a patient-specific and implant-specific customizable therapeutics 
approach to IMD drug delivery.  Sleeves must not interfere with device fixation 
mechanics and healing (typically on periosteum, or in bone) and degrade without 
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adverse incident. Biodegradable sleeves have been prepared using copolymers of 
glycolide, caprolactone, trimethylene-carbonate and lactide, containing the antimicrobial 
agents gentamicin sulfate and triclosan (highly potent bactericidal agents against S. 
aureus 204).  These sleeves slip over metallic internal fixation plates (e.g., limited contact 
dynamic compression plates) and implanted in sheep tibia with induced bone defects. 
Local release of antimicrobials to mitigate implant-associated bone infection was shown 
to kill microbes in vitro and produce no observed bone irritation or significant FBR in 
sheep in vivo 205.  A sleeve to deliver bone morphogenetic protein-2 (rhBMP-2) within 
PLGA microparticles through a porous sleeve made of resorbable polypropylene 
fumarate has also been tested 206. The porous sleeve is loaded with desired amounts of 
drug-loaded microspheres prior to implantation, with possibilities to select from a variety 
of preloaded, preformulated PLGA microsphere/drug combinations.  This strategy 
provides a case-dependent customized solution to surgeons using these over implants. 
However, this intra-operative microsphere loading technique may be produce 
inconsistent results. Multiple variants of sleeves supplied by manufacturers with 
standardized drug loading and drug delivery mechanisms may result in more 
standardized results while still allowing surgeons to choose a precise location on the 
implant to apply it for release. 
2.5.2 Customizable drug-releasing adhesive patches and intra-
operative custom coatings 
Unless performing drug formulation tasks for device addition off-label, surgeons 
are currently limited to using drug precoated and preloaded implants as received from a 
device manufacturer. These types of implants have pre-determined amounts of drug, a 
fixed drug type, and the location of the drug distributed over the implant surface cannot 
be changed or modified. Such implants are manufactured as “one-size-fits-all” and 
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generally not customizable to any particular patient or condition, or surgeon preference.  
Increasingly, combinations of multiple drugs are proving more effective than single drugs 
in a given application.  Flexibility for manipulating the drug type, drug loading and its 
location over the implant surface can be beneficial to patients receiving certain implant 
types.  New implant coating technologies to address these limitations with the flexibility 
in design and feasible intra-operative production to be readily customized to patients’ 
needs are desirable. Customizable drug-containing “paints” and patches loaded with 
desired drugs with a controlled, custom dosing and flexible application locations on a 
desired implant intra-operatively have been recently proposed 207 to provide a possible 
solution to such needs.  Adhesive drug patches fabricated from resorbable biomaterial 
laminates or composites in an aseptic environment would be loaded with drugs or drug-
loaded degradable microparticles before or during surgery and cut into desired shapes 
to match the implant, dosing and intended application.  Drug-containing polymer 
coatings could also be sprayed onto implant surfaces directly using computer-controlled 
calibrated equipment preprogrammed to match the implant specifications with patient 
needs and surgeon preferences, and applied either pre- or intra-operatively as a 
validated process.  Custom drug-release patches and drug “paintable coatings” would be 
adhered as thin films to implant sites with surgical glues at desired locations before or 
during implant surgery.  
2.5.3 Shape memory polymeric biomaterials  
Many biomedical implants are polymer-based and often require complex 
surgeries for device implantation and host integration due to their size and shape. 
Minimally invasive surgeries enable implantations of certain smaller implants with 
laparoscopes that limit patient risk, procedure cost and morbidity.  Use of biocompatible 
shape-memory polymers further provides new opportunities for improved implantation of 
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certain medical devices with relative ease and less patient discomfort. Shape memory 
processing enables specific materials chemistries to “remember” a permanent shape 
while predeformed into meta-stable temporary shapes that trigger to the permanent 
shape with a stimulus (mechanical stress, heat, light). This property allows modification 
of the device shape and size to conform to a catheter or a smaller implant readily 
inserted through smaller incisions using catheters or laproscopes than required for 
normal surgery. Nitinol is a shape memory metal commonly used in cardiovascular stent 
applications due to its ability to be deformed to a small compressed conformation 
allowing easy insertion on a catheter with minimal implantation trauma, and which 
regains its intended final shape after mechanical balloon-based deployment. Nickel 
allergy and final metal mechanical properties limit their utility.  As an alternative, 
thermally induced shape-memory polymers can be used in polymer-based suture 
applications, especially those requiring complex knots, curve shapes and conformations 
208. Shape-memory polymers have gained increased attention as a proposed biomaterial 
for minimally invasive surgical devices 208,209. Medshape (Atlanta, USA) manufactures 
FDA-approved polymer-based shape-memory implants for suture anchors and soft 
tissue fasteners. Polymer-based shape memory implants can also be used for drug 
delivery to implant locations via impregnation of desired drugs into the material and 
release upon triggering to final shape after deployment 210.  
2.5.4 See-and-treat combination imaging/drug delivery theranostic 
agents 
Some creative, new medical nanotechnology enables the possibility to combine 
the imaging, monitoring and treating of disease condition onto a single platform. 
Nanoparticles engineered with imaging agents and also containing therapeutic agents 
permit simultaneous diagnostic and therapeutic functions when circulating in vivo.  
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These so-called “theranostic” agents/devices often incorporate drug conjugates and 
complexes, dendrimers, liposomes, micelles, core–shell particles, microbubbles, and 
carbon nanotubes as carriers of either drugs or contrast agents, including optically active 
small molecules, paramagnetic metals and metal oxides, ultrasonic contrast agents, and 
radionuclides. This is an emerging area of combination devices, that could significantly 
contribute to improved disease detection and targeted therapy as well as to personalized 
medicine 211.  
Molecular imaging techniques such as magnetic resonance imaging (MRI), 
radionuclide-based imaging using computed tomography (CT) or positron emission 
tomography (PET), and high intensity focused ultrasound allow visualization and 
distinction of tissue, cellular and subcellular biological processes with the help of 
contrast agents 211. These imaging agents, combined into carriers capable of effectively 
delivering drugs to a biological target will enable a “see and treat” modality to image the 
disease condition simultaneously with triggers to delivery therapy from the agent, 
constituting a theranostic device.  
Drug conjugates or complexes with soluble polymers like poly[N-(2-hydroxyl 
propyl) methacrylamide] (polyHPMA) have been well studied 212. A contrasting agent 
visualized by magnetic resonance imaging (MRI) such as radioactive I-131, conjugated 
with the doxorubicin-HPMA polymer anti-cancer prodrug conjugate already synthesized, 
would enable the complex to be used as a tumor theranostic agent 213. Dendrimers have 
been extensively studied and are attractive drug delivery and contrast agent vehicles 
due to their large number of functional surface chemistry sites on them. Photo-activated 
drug release using dendrimers with doxorubicin conjugated to a photo-sensitive 
compound has been accomplished to target cancer 214. Other researchers have 
successfully combined dendrimers with various MRI contrast agents like high spin 
gadolinium and paramagnetic iron oxide 215. Combination of both of these chemistries 
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onto a common platform constitutes a theranostic agent.  Liposomes are another class 
of carriers recently studied as theranostic agents encapsulating various drugs and 
conjugated contrast agents 211. Multiple studies have been performed with liposomal 
formulations with targeting, therapeutic, and imaging functionalities 216,217.  
Several other colloidal and nanoparticulate carriers like polymersomes, micelles, 
quantum dots, and carbon nanotubes can be conjugated with drugs and imaging agents 
for treating a condition simultaneously with detection and diagnosis 211. While the dual 
conjugation chemistry is fairly straightforward in many cases, the challenge remains to 
produce long circulating times to allow these particulate systems to achieve disease site 
accumulation.  The concept of targeting these particles has proven very challenging to 
date, with very low levels of systemically administered dose (i.e., generally less than 5% 
of the injected dose) actually reaching the disease site from the blood stream, with the 
majority of the dose targeting the liver, spleen, kidney and lung in most cases.  Imaging 
requires sensitivity, selectivity and specificity in vivo 218. Therapy requires effective dose 
delivery without toxic side effects.  Building both critical properties onto a single 
nanoparticle platform is challenging: these two properties are not yet reliably achieved 
from these nanoparticle systems.  
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Figure 2.1: General host-interfacing challenges facing implanted medical devices. 
 
Figure 2.2: Illustration of the temporal series of host biological events during the host foreign 









Figure 2.3: Extrinsic and intrinsic cascades for the zymogens, active proteins, and clotting 
factors mediating clot formation after procoagulant stimulus.  
 
Figure 2.4: Bacterial seeding, colonization, biofilm transformation, differentiation, maturation, 







Table 2.1:  Diversity of combination medical products used in physical or chemical 
combinations, or co-packaged as a kit, or as separate cross-labeled products. 
 
Combination product type Clinical examples 
Drug and device Drug-eluting stents, antimicrobial catheters, 
tibial nail, and sutures  
Drug and biologic Autologous platelet concentrate delivery of 
gentamycin to a open fracture; demineralized 
bone matrix delivery of statins to bone defect 
Biologic and device Heparin-coated vascular grafts, insulin 
infusion pumps, spinal cages with rhBMP-2 
Drug and biologic and device (No precedents approved); fictional example: 
adenoviral NfkB transgene delivery from 









Figure 2.5: Bioactive heparin-immobilized surface capable of inhibiting thrombin activation, a 
key mediator in clot formation.  The strategy is used for blood-contacting devices to limit 
complications from device-based thrombosis. (adapted from illustration of CarmedaTM coating, 
W.L. Gore & Associates, USA) 
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Mast cells are recognized for their functional role in wound healing, allergic and 
inflammatory responses, host responses that are frequently detrimental to implanted 
biomaterials if extended beyond acute reactivity.  These tissue reactions are especially 
impacting to the performance of sensing implants such as continuous glucose 
monitoring (CGM) devices.  Our hypothesis that effective blockade of mast cell activity 
around implants could alter the host foreign body response (FBR) and enhance the in 
vivo lifetime of these implantable devices motivated this study. Stem cell factor (SCF) 
and its ligand c-KIT receptor are critically important for mast cell survival, differentiation, 
and degranulation.  Therefore, a mast cell-deficient sash mouse model was used to 
assess mast cell relationships to the in vivo performance of CGM implants.  Additionally, 
local delivery of a tyrosine kinase inhibitor (TKI) that inhibits c-KIT activity was also used 
to evaluate the role of mast cells in modulating the FBR.  Model sensor implants 
comprising polyester fibers coated with a rapidly dissolving polymer coating containing 
drug-releasing degradable microspheres were implanted subcutaneously in sash mice 
for various time points, and the FBR was evaluated for chronic inflammation and fibrous 
capsule formation around the implants. No significant differences were observed in the 
foreign body capsule formation between control and drug-releasing implant groups in 
mast cell-deficient mice. However, fibrous encapsulation was significantly greater around 
the drug-releasing implants in sash mice compared to drug-releasing implants in wild-
type (e.g., mast cell competent) mice.  These results provide insights into the role of 
mast cells in the FBR, suggesting that mast cell deficiency provides alternative pathways 






Host foreign body response (FBR) to implanted biomaterials plagues the 
performance of several implanted biomedical devices, particularly soft tissue sensor-
actuator type implants such as pacemakers and continuous glucose sensors.  The FBR 
is mediated by a complex series of tissue inflammatory events modulated by several cell 
types recruited as part of the normal wound healing process.  Dissolution, degradation, 
and/or complete phagocytosis of certain foreign objects (e.g., pathogens, foreign 
proteins, nano- and microparticles) resolves the FBR and normal wound healing is 
restored.  Implants with prolonged tissue residence, generally lacking the ability to be 
cleared from a tissue site via natural mechanisms, alter the tissue wound healing 
response in chronic inflammatory conditions, producing fibrous encapsulation of the 
foreign body and hallmark foreign body giant cells [1].  Fibrous encapsulation often 
isolates the implanted foreign body from normal host tissue sites.  This capsule is dense 
and frequently poorly vascularized, altering sensor electrical responses, blocking 
transport of analytes to sensors, compromising functional performance, and disposing 
these sites to infection. 
The intensity and impact of the FBR depends upon recruitment and reactivity of 
several key cell mediators, including polymorphonuclear neutrophils (PMNs), 
monocytes, macrophages, mast cells, and fibroblasts [2].  Each cell type has a specific 
role in modulating the local tissue response to wounding (i.e., implant placement) and 
subsequent healing, including chronic inflammation and the FBR [3]. The role of mast 
cells (MCs) in the FBR is associated with mediating the host response by secreting 
cytokines and cell mediators through cell activation and degranulation of their prominent 
intracellular granules [2]. MC precursors derive from hematopoietic stem cells in the 
bone marrow and are recruited through chemotactic inflammatory signaling to wound 
sites where they mature and activate. MCs are found ubiquitously in all tissues, 
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particularly associated with vasculature and nerves, and also in proximity epithelial 
surfaces such as airways and skin. MC survival and differentiation depends on 
presentation of the ligand of their membrane-resident c-KIT receptor also known as stem 
cell factor (SCF) [4-6]. The c-KIT receptor is primarily expressed on hematopoietic stem 
cells and mast cells [7]. SCF/c-KIT interactions result in mast cell activation and 
degranulation, prompting secretion of vasodilators (histamine), chemokines, cytokines 
(e.g., IL-4, IL-13) and prostaglandins [8-11].  
MCs act as a primary cell-based host defense mechanism, mediating allergic 
responses and inflammatory responses. They have also been shown to influence 
neovascularization and tissue remodeling [12]. MC degranulation in the presence of 
antigens or allergens produces cell secretion of granules containing IL-4 and IL-13 that 
provide chemotactic gradients to recruit macrophages, and histamine and serotonin to 
dilate the vasculature to facilitate greater access to the inflammatory cells arriving at the 
wound site [2].  
The MC role in the implant-associated FBR was recently described using a wild-
type C57BL/6 mouse subcutaneous model and a local pharmacological approach.  
Inhibition of tissue site MC activation and degranulation was attempted using local 
delivery of a tyrosine kinase inhibitor, masitinib [13]. Reduced thickness of the foreign 
body capsule formed around implants was demonstrated in vivo for up to 28 days post-
implantation.  A similar study using hernia mesh implants [14] demonstrated that 
blocking mast cell degranulation with cromolyn treatment reduced inflammation and 
fibrosis around the subcutaneous implant site.  In the context of CGM sensor implants, 
Klueh et al. [15] recently probed the MC role in the performance of implanted CGM 
sensors in murine cutaneous implant models. When compared to MC-sufficient wild-type 
C57BL/6 cohorts, implants in their knockout Kitw-Sh (sash) (MC-deficient) mutant mice 
exhibited stable CGM responses for up to 28 days, suggesting a critical MC role in 
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modulating host tissue response to implanted sensors.  Mechanisms for this observation 
require further study and elucidation. 
Previous studies in MC-deficient sash mice also show normal wound healing in 
cutaneous wounds in the absence of mast cells [16]. Our prior work describes thinner 
fibrous capsule formation around masitinib-releasing implants than that around control 
implants in wild-type mice, suggesting that stabilizing MCs alone does not completely 
avoid FBR fibrosis [13]. These results have produced a further idea that the use of a 
MC-stabilizing drug in wild-type mice might alter the local tissue response to implants, 
but may not completely avoid it as fibrous encapsulation of foreign implants has also 
been observed in the absence of MCs [15, 16]. Klueh et al. [15] report dramatically 
reduced inflammation and fibrosis around subcutaneous implants in mast cell-deficient 
mice, while Nauta et al. [16] observed no discernable differences in collagen 
concentrations in the scar tissue around cutaneous wound sites among MC-deficient 
and analogous wild-type mice. However, wound healing models in these two studies 
were significantly different: CGM sensor insertion requires an approximate 600 µm-
diameter percutaneous access [15] while cutaneous wounds [16] were 6 mm in 
diameter. Interestingly, glucose sensor CGM implants functioned normally even with 
early capsules surrounding them, indicating that the early capsule is permeable to 
essential analytes (i.e., glucose and oxygen for this CGM) required for glucose sensing. 
Additionally, these studies have diametrically opposite conclusions regarding the role of 
MCs in modulating the FBR.  Hence, this strategy needs further investigation to 
understand the complex MC mechanisms involved in FBR and if they can be exploited in 
the context of implant-associated healing and device integration. 
Here, we evaluate the effect of the c-KIT-inhibiting drug, masitinib, in implant-
associated MC functions in MC-deficient mutant sash mice.  The intent is to assess the 
role of MCs in host tissue responses to implanted biomaterials. Masitinib is a relatively 
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new tyrosine kinase inhibitor shown to be an effective inhibitor of MC proliferation in vitro 
and in vivo [17] and therefore was chosen to release from the implanted CGM interface 
to inhibit mast cell degranulation in a device-based local delivery formulation. Apart from 
being a potent inhibitor of c-KIT, masitinib has also been shown to inhibit platelet-derived 
growth factor receptor (PDGFR), intracellular kinase Lyn, and fibroblast growth factor 
receptor 3 (FGFR3) that play a role in tissue remodeling, inflammatory, and allergic 
responses [17]. 
Mast cell-deficient sash mice (B6.Cg-KitW-sh/HNihrJaeBsmGlliJ) have been 
used as the strain of choice for studying MC deficiency-related conditions [18]. In this 
context, polyester fiber model implants as sensor surrogates were coated with rapidly 
dissolving polymer film loaded with degradable polymer microsphere controlled release 
formulations of masitinib to alter the healing dynamics in subcutaneous tissues of mast 
cell-deficient sash mice implanted for 14, 21, and 28 days. 
4.3 Materials and Methods 
4.3.1 Materials  
Poly(lactic-co-glycolic acid) (PLGA) was purchased from Lakeshore Biomaterials 
(now Evonik Biomaterials, USA). Polyethylene glycol (PEG) (MW 20,000), polyethylene 
oxide (PEO) (MW 100,000), poly(vinyl alcohol) (PVA, average MW 30-70 kDa), and 
solvents dichloromethane (DCM), chloroform, ethanol, methanol, and acetonitrile were 
purchased from Sigma Aldrich, USA. Trifluoroacetic acid (TFA) was purchased from 
Fisher Scientific, USA. Masitinib drug was purchased from Selleck Chemicals, USA. 
Commercial polyester fiber (Trilene, 300 µm diameter, Berkley Fishing, USA) was 
cleaned using 70% ethanol before use.  Ultrapure water (Millipore-filtered ASTM Grade 





4.3.2 Implant fabrication  
Implant fabrication was accomplished as described in a recent publication [13]. 
Briefly, PLGA polymer microspheres were fabricated using established solvent-
evaporation techniques either with masitinib at a concentration of 1 mg/ml or without 
masitinib (blank controls), and mixed with aqueous PEG/PEO solution at a concentration 
of 350 mg/ml. Polyester fiber sensor model implants were coated with the PEG-PLGA 
microsphere solution using a 2-part aluminum mold and flash-freezing, and the resulting 
coating was lyophilized for 12 hours to obtain the implants coated with a rapidly soluble 
polymer film containing drug-loaded microspheres. Both drug-releasing and control 
implants (i.e., PLGA microspheres, no drug) were fabricated using this procedure.  
Intended masitinib load within each implant was calculated based on drug dosing 
values from Dubreuil et al. [17], with subcutaneous tissue density values obtained from 
Kyrzywicki et al. [19], and assumptions about the intended tissue delivery volume 
surrounding the implant (see Figure 4.1A).  A dose of 60 mg/kg/day was considered 
potent by assuming complete drug clearance each day from the tissue bed surrounding 
the implant. Subcutaneous tissue density of 1 g/cc and a targeted tissue drug exposure 
depth of 200 µm around each implant (illustrated in Figure 4.1A) were considered, and 
the resulting dosing values were extrapolated for 30-day release for targeting final drug 
load on the implant. A margin of safety of 1.5x was used in calculating the drug 
loading/implant to accommodate this required drug load and assumptions.  Post-
fabrication, coated implants were tested for viable bacterial contamination using blood 
agar cultures for a 24-hour incubation period. USP chromogenic LAL assay (Lonza, 
USA) was used to test for endotoxin content on the final implants.  
Drug loading and release for each implant was characterized using high 
performance liquid chromatography (HPLC) and a UV detector at 283nm for masitinb. A 
Zorbax Eclipse C18 column (4.6 mm × 250 mm, 5µm, Agilent Technologies, USA) was 
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used for drug quantification using a method with 2 mobile phases (A and B) developed 
with a 30-minute cycle time. TFA in water (1%) was used as mobile phase A and TFA in 
acetonitrile (1%) was used as mobile phase B. The HPLC assay involved gradient flow 
of mobile phase B at 100% initially and ending the cycle at 0% (100% mobile phase A) 
at a flow rate of 1 ml/min. 
4.3.3 In vivo implant studies  
Male sash (B6.Cg-KitW-sh/HNihrJaeBsmGlliJ) mice (12-14 weeks) were 
purchased from Jackson Laboratories (USA). Animals were divided into 3 cohorts for 14, 
21, and 28-day study time points with n=7 for each time point. Each animal was 
implanted subcutaneously with one blank control and one masitinib-releasing sensor 
model implant parallel to the spine in the dorsal regions, as illustrated in Figure 4.1B.  All 
procedures involving the use of animals for this study were approved by the institutional 
animal care and use committee (IACUC) at the University of Utah.  
Surgical implant procedures were adapted with slight modifications from that 
recently published in a similar context [13, 20]. Each animal was anesthetized using 1-
2.5% isofluorane (in 1 L/min of oxygen) administered through a nose cap throughout the 
procedure. Animals were placed on a warming water pad to maintain body temperature 
for the duration of surgery and recovery. An area of 6×4 cm2 on the back of the animal 
was shaved and the exposed skin treated with povidone-iodine solution to create an 
aseptic environment at the surgical site. A sterile 18G needle was used to gently 
puncture the skin and to inject the wound site with 100 µl of pyrogen-free 0.9% NaCl 
solution to create a subcutaneous “pocket” for the implantation procedure. The implant 
was gently inserted through the puncture into the subcutaneous pocket created with the 
NaCl solution such that the entire implant is placed subcutaneously under the animal’s 
skin without any protrusions, and the perforated skin was then sealed with skin glue 
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(Nexcare Skin Care, USA). The animal was then removed from anesthesia and allowed 
to recover on the warming pad before being moved to its cage. Animals were housed in 
individual cages in 12-hour dark/light cycles for the duration of the study; food and water 
were provided ad libitum. Implanted mice were divided into 3 cohorts with different study 
end points of 14, 21, and 28 days.  
4.3.4 Explant histological analysis  
At each time point, animals were euthanized using 100% CO2 in a bell jar and the 
entire tissue bed surrounding each implant including the implant was harvested intact for 
histology. Harvested tissue was fixed in 10% neutral buffered formalin (Fisher Scientific) 
for 48 hours with the formalin being replaced after 24 hours. The fixed tissue was then 
sent to Associated Regional and University Pathologists (ARUP, USA) Laboratories for 
further processing and histological analytical guidance. Tissue samples were sectioned 
and stained with hematoxylin and eosin (H&E) stain to identify cell nuclei and to quantify 
inflammatory cell densities, and with Masson’s trichrome stain to identify fibrosis and to 
quantify capsule thicknesses around implants.  
4.3.5 Inflammatory cell densities measurement  
Cell densities on H&E-stained sections of implant tissue were determined 
microscopically by scoring the number of cells surrounding each implant in five 
representative 40x fields per sample. Cell density was expressed as a representative 
score of the number of cells present per field. Neutrophils and plasma cells, 
macrophages and foreign body giant cells, and fibroblasts were identified visually by 
morphology and scored at radial distances of 50 µm, 150 µm, and 300 µm from the 
implant/tissue interface for both control and masitinib-releasing implants. These cells 
were chosen to represent those typical of the foreign body response, with neutrophils 
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representing the acute wound stage infiltrates, while macrophages and fibroblasts 
represent more chronic FBR and tissue resolution stages, respectively [2].  
4.3.6 Capsule thickness measurement 
Tissue sections stained with both H&E and Masson’s trichrome were observed 
under bright field microscopy using 10x and 20x objectives, and images were captured 
and analyzed. Capsule thickness from fibrosis around each implant was measured at the 
interface of the implant and adipose tissue on the apical side, and also the interface of 
the implant and muscle tissue on the basal side. Multiple random locations (n=5 per 
implant site, N=7 implants) at these interfaces were chosen for the capsule thickness 
measurements using ImageJ software. Capsule thicknesses are also compared with 
values obtained around identical implant sites in MC-competent mice [13] to analyze the 
effect of locally released masitinib on subcutaneous murine fibrosis in the presence and 
absence of MCs. 
4.3.7 Statistical significance  
All data are expressed as the mean ± 1 standard deviation and compared with an 
ANOVA test. Capsule thickness data for control implants were compared with masitinib-
releasing implants for identical time points using Student’s T-test assuming equal 
variance.  Data were considered statistically significant for p< 0.05. 
4.4 Results 
4.4.1 Implant fabrication and characterization  
PLGA microspheres (5-20 µm diameter) were obtained from the fabrication 
method [13]. This size range is generally accepted to be beyond the phagocytosable 
range of tissue site phagocytes [21, 22] eliminating confounding effects of undesired cell 
particle uptake and processing.  
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An aqueous mixture of PEG/PEO solution and PLGA microsphere suspension 
was used to coat polyester fiber model implants using 2-part aluminum molds and 
cryogenic processing to produce the resulting implant matrices [13]. The resulting PEG-
PLGA composite coatings were previously shown to dissolve in vitro in less than 3 
minutes [13]. The PEG-PLGA microsphere-coated implants were characterized for drug 
loading and release using HPLC analysis. Masitinib loading in the PLGA component of 
the composite implant coating was determined to be 11.2±1.2 µg/implant (mean ± 
standard deviation, n=3) by HPLC analysis (LOD = 73 ng/ml). This dosing is ~1.5X the 
theoretically calculated dose required to target mast cells in a 200 µm-thick tissue 
volume surrounding the implant site at a desired loading of 7.5 µg/implant, assuming 
complete tissue site clearance each day over the dosing interval. Blood agar cultures 
with the implants showed no bacterial colony formation after 24 hours of culture. LAL 
assay results show endotoxin content less than 0.1 ng/implant – a negligible amount 
compared to the reported endotoxin clearance rate of 5 ng/kg/hr [23]. 
4.4.2 Inflammatory cell densities around implants in vivo   
H&E-stained tissue preparations exhibit variable distributions of different 
inflammatory and wound-recruited cell densities for both control and masitinib-releasing 
implant sites at each time point, as shown in Figure 4.2.  Inflammatory cell densities 
around the implant site were scored for 3 cell types: neutrophils (PMNs), macrophages 
and foreign body giant cells (FBGCs), and fibroblasts, all representative of the acute 
inflammation, chronic inflammation, and tissue remodeling phases of the FBR, 
respectively.  
Observed tissue site cell densities for control (PLGA blank, no drug) vs. drug 
loaded composite implant coatings for these different cell types were evaluated for 
different time points: 14 days, 21 days, and 28 days, at distances of 50 µm, 150 µm, and 
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300 µm from implant-tissue interface. Cell densities were scored in arbitrary units (a.u.) 
as 1-normal, 2-moderate, 3-medium, 4-high, and 5-severe by direct observation of 
multiple randomly selected histological sections from sash mast cell-deficient mice. 
Cell density assessment for the 14-day time point in sash mast cell-deficient mice 
is shown in Figure 4.3A. Around control implants, PMNs exhibit high densities at the 
implant surface and decrease in numbers with increasing distance from the implant 
surface. This trend is seen in all cell types analyzed in this study around the control 
implants. For drug-releasing implants, PMNs and fibroblasts are found in high numbers 
in zones at greater distances from the implant site (i.e, from 50 µm to 150 µm) – not 
directly at the implant interface - and decrease in density further away from the implant 
surface (to 300 µm). Macrophages around drug-releasing implants steadily decrease in 
density with increasing distance away from the implant while their numbers peak around 
the PLGA microspheres at 150 µm and decrease at 300 µm distances from control 
implant surfaces.  
The 21-day time-point cell density profile is shown in Figure 4.3B but in contrast 
to earlier time points exhibit no clear trends among the different cell types surrounding 
both the control and drug-loaded implants in sash subcutaneous tissue. In the control 
implant group, PMN cell density increases consistently with increasing distance from the 
implant, whereas macrophage density initially increases and then decreases over the 
same measured distance.  Fibroblast numbers remain steady until 150 µm distance from 
the implant and then decrease to 300 µm. In the drug-loaded group, PMN density is 
roughly constant to a distance of 150 µm and then increases slightly, similar to their 
corresponding density in the control implant group. Macrophages are roughly constant at 
50 µm and 150 µm and then decrease at 300 µm distance from the implant. Fibroblasts 
initially increase near the implant and then decrease from 50 µm to 300 µm.   
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For the 28-day time point (Figure 4.3C), PMN cell density increases slightly from 
the control implant surface and then remains constant from 150 µm to 300 µm.  In 
contrast, PMN density is constant around the drug-loaded implants at any distance.  
Macrophage density is comparable among the drug-loaded and control implants from 50 
µm to 300 µm.  Fibroblast density decreases between 150 µm and 300 µm for the 
control implants and increases between the same distance points around drug-loaded 
implants. 
Overall, the qualitative analysis shows a comparable cell density profile between 
control and drug-loaded implant sites, with most tissue locations exhibiting similar or ±1 
a.u. difference in cell density scores.   
4.4.3 Implant capsule thickness  
Masson’s trichrome-stained (MTC) histology preparations were used to measure 
fibrous capsule thickness formed around implants at the different explant time points. 
Capsule thicknesses were measured at multiple locations between the arrows, as shown 
in Figure 4.4A-4.4F. Figure 4.4G shows capsule thickness plots for both implant types at 
respective time points. Capsule thickness values are averaged for measurements taken 
from 5 random locations on each implant site in 7 individual implant sites (i.e., n=5 for 
N=7). Capsule thickness values for control implant sites were found to be 42.5±5.6 µm, 
34.6±6.3 µm, and 41.6±5.2 µm for 14-, 21-, and 28-day time points, respectively.  
Thicknesses were 38.9±11.5 µm, 34.4±6.2 µm, and 42.4±6.2 µm for capsules around 
the masitinib-releasing implant sites for these same respective time points. These 
measurements do not show statistically significant differences between control and 




4.4.4 Comparisons of implant fibrosis between mast cell-
competent wild-type and sash mast cell-deficient implant sites 
Capsule thickness values for 14-, 21- and 28-day time points for both the control 
and masitinib-releasing implants compared for MC-competent and sash MC-deficient 
mice are compared in Figure 4.5 [13]. For identically prepared implants in the wild-type 
mice, capsule thickness values for control implant sites were found to be 42.2±4 µm, 
60.2±6.9 µm, and 53.2±17.4 µm for 14-, 21-, and 28-day time points, respectively.[12]  In 
contrast, capsule thicknesses were substantially reduced to 11.7±1.1 µm, 14.4±4.7 µm, 
and 14.4±6.3 µm for tissue around masitinib-releasing implant sites in wild-type MC-
competent mice.  In sash MC-deficient mice, fibrous capsule thickness values around 
control implants were comparable to that in wild-type mice except for the 21-day time 
point.  Interestingly, values for capsule thicknesses around masitinib-releasing implants 
in sash mice were significantly higher than in the same drug-releasing implants in wild-
type mice at the same time points.  
4.5 Discussion 
We report in vivo influences of local release of the tyrosine kinase inhibitor, 
masitinib, at subcutaneous implant sites in MC-deficient sash mice to evaluate the 
possibility to eliminate MC effects on the FBR.  This has been motivated by the need to 
improve performance from implanted feedback and reporting devices such as CGM 
sensors that are adversely affected by tissue site FBR. The rate of CGM adoption by 
patients to monitor glycemic indices and mitigate long-term effects of diabetes is 
increasing.  The effects of host response on these implanted devices has limited their 
FDA-approved lifetimes to less than a week in tissues.  Evidence from several studies 
shows that MCs play an important role in mediating the wound healing response to 
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implanted biomaterials [24].   Pharmacological influences on MC function at implant sites 
could provide new insights into FBR and implant response.  
In this regard, recent studies by Klueh et al. [15] have shown reduced FBR to 
implanted CGM sensors in sash mouse models deficient in MCs. Specifically, they have 
shown uninterrupted CGM response over a 28-day period in sash mice that was only 
lost when bone marrow-derived MCs were injected at the implant site, suggesting the 
importance of MCs in modulating the FBR. We tested their theory by seeking to replicate 
their results using local drug release to inhibit mast cell degranulation at the implant site. 
Our previous study [13] showed that local delivery of MC-targeting masitinib from 
surfaces of implanted model sensors reduced capsule formation around subcutaneous 
implant sites in wild-type mouse models. This study now extends that approach in MC-
deficient sash mice mutants to understand FBR pharmacological modulation in the 
absence of MCs. 
4.5.1 Inflammatory cell densities at the implant-tissue site   
The model implant used in this study is a cleaned, endotoxin-free cylindrical 
monolithic polyester fiber with low surface area that is coated with a rapidly soluble PEG 
layer containing porous PLGA microspheres as drug carriers. This coating is not 
crosslinked and highly soluble, allowing immediate dissolution and disintegration upon 
implantation to disperse the PLGA contents into the local tissue bed surrounding the 
implant.  This results in no interference with CGM function if used in the context of a 
sensor.  It also results in tissue site deposition of two very different types of foreign 
bodies, i.e,, a low surface area monolithic polymer fiber, and a low-density, high surface 
area degradable polymer microsphere. Previous literature has shown that FBR to high 
surface area implants proceeds at a slower rate, as infiltrating inflammatory cells require 
more time to traverse through the porous structure of such implants [3, 25]. The 
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presence of significant PMNs around the 28-day tissue explant sites (Figure 3C), a cell 
type typically not found after this time duration around implants, can be attributed to this 
phenomenon. Cell density analysis for the 14-day study (Figure 3B) shows increasing 
PMN density moving away from the implant-tissue interface, suggesting the dispersed 
presence of PLGA microspheres around the implant site. This observation helps explain 
the variations in cell densities around implant sites as the local densities around PLGA 
foreign bodies are different from the average densities in adjacent tissues.  
Since the host inflammatory responders encounter two distinct implant types (i.e,, 
polymer monolithic fiber and porous PLGA microspheres), FBR modulation is distinct for 
each of them. The local variations in implantations and tissue bed distributions of implant 
coating contents from the implant, and cell densities for various cell types are 
comparable between control and drug-loaded implant sites for a given time point.  
Observed PLGA microspheres located at distances of 150 µm from the implant surface 
indicate that their drug load is released to tissue some 200 µm from the implant 
interface. This can be correlated to the increase in inflammatory cell densities observed 
at 150 µm from the implant surface, as seen in Figure 4.3. 
4.5.2 Capsule thickness  
Capsule thicknesses compared in this study for sash MC-deficient mice show no 
significant differences between control and drug-loaded implant groups. Interestingly, no 
appreciable changes in capsule thicknesses are seen at the 14-, 21- and 28-day time 
points.  This result is distinct from that show previously for identical implants in wild-type 
MC-competent mice [13], indicating distinct differences in subcutaneous tissue 
pharmacology to masitinib in MC-deficient mice. MC absence in the sash models could 
facilitate different inflammatory reactions and tissue remodeling kinetics, possibly due to 
absence of MC-derived vasoactive agents normally that permit greater influx of 
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inflammatory cells to the injury/implantation site. Interestingly, capsules around drug-
loaded implants in wild-type mice are thinner than their analogous capsules in the sash 
MC-deficient mice [13]. Capsule thickness data from Figure 4.4G can be correlated to 
the fibroblast cell densities around implant sites in Figure 4.3. Fibroblast density at 50 
µm from the implant surface increases from 14 to 21 days and then attenuates at 28 
days to the 14-day levels, suggesting that fibroblast density undergoes little to no net 
change for the various time points. 
Several studies have shown comparable cutaneous wound healing in wild-type 
and MC-deficient mice [16, 26, 27].  The effects of MC-absence on wound healing have 
been debated to have either positive or negative impacts on tissue remodeling 
processes [16, 24].  MC injections at the implant site have shown to precipitously drop 
CGM sensor response in both wild-type and sash mice, suggesting that their presence 
intensifies collagen formation or results in increased vasoconstriction, limiting blood flow 
to the implant site [15].  
Results from this study showing that collagen formation around implants is not 
being affected by masitinib release supports either that the drug is mainly targeting MCs 
and hence ineffective in their absence in the sash model, or that the FBR in sash mice is 
independent of the various targets of masitinib (i.e., FGFR3, PDGFR, Lyn kinase) - all of 
which have been shown to be interdependent on MC activity [17, 28, 29]. As an indicator 
of common TKI bioactivity pathways, masitinib mesylate has been shown to reduce 
production of extracellular matrix and prevent the development of experimental non-
implant fibrosis [30]. Nonetheless, masitinib is selective in inhibiting recombinant human 
c-KIT receptor (IC50 200	 ± 40nM), and platelet-derived growth factor receptor (PDGFR) 
while weakly inhibiting other type III tyrosine kinase receptors, including fibroblast growth 
factor receptor 3 (FGFR3) and FCεRI receptor. Imatinib inhibits a broader range of 
receptors [17]. These receptors when bound to ligands like IgE, SCF, C3a, PAMPs, etc., 
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result in mast cell activity and degranulation [31], leading to increased inflammatory cell 
activity. In the absence of mast cells in sash mice however, masitinib appears to be 
ineffective in regulating collagen production by fibroblasts. This could mean that sash 
mice have developed an alternative wound site inflammatory response system acting 
mostly independently of MC activity. 
4.6 Conclusions 
The absence of MCs in the sash mouse implant response does not significantly 
alter the fibrous encapsulation of implanted biomaterials. The use of local masitinib as a 
TKI capable of inhibiting c-KIT receptors on MCs and other cells does not alter FBR 
perceptibly in the absence of MCs as evidenced by the similarity in inflammatory cell 
densities around drug-releasing and control implant sites. Similarly, fibrous capsule 
formation around implanted biomaterials shows similar thicknesses around control and 
drug-releasing implants in the MC-deficient sash model. Correspondingly, capsule 
thickness is almost constant over time, correlated with the constant fibroblast cell density 
observed around the implants as implant time increases.  Capsule thickness around 
drug-releasing implants in sash mice is higher when compared to thickness values 
around analogous drug-releasing implants in wild-type mice, suggesting an alternative 
pathway for inflammatory responses in mast cell-deficient mice that proceeds to rapid, 
reliable fibrosis as an expected FBR endpoint in the absence of MC mediators.  This 
indicates that the pathways that recruit and stimulate fibroblast deposition of matrix, 
especially collagens, in the sash model must be highly operative. 
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Figure 4.1: Illustration of implant and locations of implantation. (A) Implant drug-
loading calculation geometric volume model used for drug dosing to local tissue sites 
into 200-micron thick cylindrical tissue volume adjacent to the implant, and (B) 
bilateral dorsal implant locations in a sash knock-out mouse. 
 
 
Figure 4.2: H&E stained histology slides showing subcutaneous tissue sites around 
A), C) and E) control (PLGA microparticle blank) PEG polymer-coated implants and 
B), D) and F) PLGA microparticle drug-loaded, PEG-polymer-coated implants for 14, 
21, and 28-day implants in sash mast cell-deficient mice, respectively. The ‘*’ symbol 







Figure 4.3: Inflammatory cell densities of representative cells contributing to the 
foreign body response as a function of distance from the implant-tissue interface for 






Figure 4.4: Masson’s trichrome stained histology slides showing subcutaneous tissue 
sites around A), C), and E) control (PLGA microparticle blank) PEG polymer-coated 
implants and B), D), and F) PLGA microparticle drug-loaded, PEG-polymer-coated 
implants for 14, 21, and 28-day implants, respectively. The ‘*’ symbol represents the 
implant site.  Magnification is 20x and scale bar is 200 µm. G) Comparison of foreign 


















Figure 4.5: Comparison of foreign body capsule thickness between wild-type (taken 
from data reported in Ref. 12 and plotted here) and sash mast cell-deficient mice for: 
A) control, and B) drug-loaded implant sites. *p < 0.05. 
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Continuous glucose monitoring (CGM) sensors have long been recognized as 
beneficial for improving long-term glycemic control in the context of diabetes. 
Subcutaneous sensor fouling and fibrous encapsulation resulting from the host foreign 
body response (FBR) reduces sensor sensitivity to glucose and eventual produces 
sensor failure. Several combination device strategies have been evaluated using CGM 
sensors that release drug payloads locally to tissue sites to mitigate FBR-mediated 
sensor failure. Here, the mast cell-targeting tyrosine kinase inhibitor, masitinib, was 
released from polymer microspheres delivered from the surfaces of commercial CGM 
needle-type implanted sensors. Targeting the mast cell c-Kit receptor and inihibting mast 
cell activation and degranulation, the local masitinib delivery around the CGM sought to 
reduce fibrosis around the sensor and extend its functional lifetime in subcutaneous 
sites. Drug-releasing and control CGM implants were tested in murine percutaneous 
implant studies for 21 days continuously.  Drug-releasing implants showed reduced 
fibrosis around implant sites and relatively stable sensor responses over the period of 
the study compared to blank microsphere controls. 
5.2 Introduction 
  Nearly 350 million people (5% of world population) suffer from diabetes 
worldwide [1], including the 25.8 million Americans (8.3% of the population) who require 
regular glucose monitoring. Tight regulation of blood glucose has been convincingly 
shown to reduce diabetes morbidity and mortality [2], leading to a standard of care that 
demands intensive glucose monitoring. While most glucose monitoring involves painful, 
inconvenient finger sticks to extract blood, subcutaneous continuous glucose monitoring 




  Currently, four subcutaneous CGM systems are approved for patient self- 
implantation and marketed, with “real-time” glucose reporting every 1–5 minutes, and 
with alarm functions for hypo- and hyperglycemia [7, 8].  Three CGMs are needle-type 
subcutaneous designs: the Freestyle Navigator (Abbott Diabetes Care, Alameda, CA), 
the Guardian Real-Time (Medtronic MiniMed, Northridge, CA) [9-11], Dexcom G4 
Platinum (Dexcom, San Diego, CA). The fourth (GlucoDay, Menarini Diagnostics) is a 
microdialysis-type sensor.  All commonly measure glucose in situ amperometrically via 
the classic Clark glucose oxidase reaction [4-6].  However, as this analyte reaction 
requires co-transport of tissue glucose and oxygen to the electrode buried within the 
needle sensor membrane in order to produce the redox chemistry required for sensing, 
interference with either transport or with the redox chemistry proves problematic to 
reliable glycemic reporting.   
Among several clinical CGM interferents, the host foreign body response (FBR) 
remains most problematic, limiting human performance to several days once implanted.  
The FBR involves a complex set of cascades of cell reactions and cytokines in the 
implant site.  Initially, the acute host response is essentially a normal wound healing 
response to address the wound created by the implant placement.  This immediate 
inflammatory response around the CGM produces confounding influences on glucose 
response until the acute local tissue reaction subsides to steady state – a phenomenon 
called “burn in” [7, 12, 13]. However, without implant removal or complete degradation, 
this acute response to the implant transitions to a chronic inflammatory response that no 
longer resembles wound healing but has distinct features, including release of 
inflammatory cytokines IL-4 and IL-13 that accelerate recruitment of inflammatory and 
immune cells to the implant site [14], formation of unique foreign body giant cells, and 
finally, fibroblasts that deposit excess collagen and matrix proteins [14-18]. The endpoint 
of this chronic host response is a fibrous sheath that surrounds the implant, many tens of 
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microns thick and avascular [17, 19, 20]. This physical collagenous barrier formation 
(shown in Figure 5.1) frequently hinders analyte transport between host tissue and the 
CGM, limiting the functional lifetime of this device in subcutaneous sites [14].   
As a result of the host-implant response, regulatory approvals for most of these 
devices in humans are several days instead of the weeks-to-months shown to 
characterize reliable CGM operation reliably in vitro. Significantly, all four FDA-approved 
sensors exhibit instability over the approved implantation and sensing period (3-7 days), 
and their pre-implant single-point calibration is thought to be good for only 12 hours [7].  
Despite intensive research over two decades, CGM glucose sensing performance under 
sustained chronic implantation (>14 days) remains a major challenge primarily due to the 
host’s acute and chronic foreign body response (FBR) to the implanted sensor.  Given 
the current performance issues dogging CGMs, barriers to expanding their clinical utility 
and patient benefits are notable. Longer-term implantable CGM sensors would facilitate 
the development of a closed-loop glucose sensor–insulin pump system that could 
improve the quality of life of millions of diabetes patients as an artificial pancreas with 
dynamic, feedback-driven response [21]. 
Strategies to improve CGM sensor lifetimes in tissue have focused on refined 
signal processing [22], improved surface fouling resistance by applying specific coatings 
to sensor surfaces to inhibit protein and cell adhesion [17, 23], CGM device design 
refinements, and modifying the CGM as a combination device that releases a drug 
payload locally from the implant modify local cell and tissue reactions [24-27].  To date, 
none of these approaches has demonstrated profound changes in the host implant site 
response to improve CGM functional duration.   
CGM surface coatings containing bioactive nitric oxide [28-30], dexamethasone 
[31-33], and vascular endothelial growth factor (VEGF) [34, 35] both attempt to limit 
sensor fouling while exploiting a local pharmacological strategy to attenuate the intensity 
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of the acute phase host inflammatory reaction.  Each locally released drug and 
associated coating matrix approach has formulation, loading, and stability issues, 
different dosing requirements for given potencies, and different tissue targets.  
Dexamethasone seeks to inhibit fibroblast production of collagen around the sensor, 
while VEGF prompts local angiogenesis to endow the FBR fibrotic capsule around the 
sensor with effective permeability, sufficiently perfused for effective trans-capsular 
glucose and oxygen transport to the sensor.  Significantly, these drug-release 
approaches have addressed cell targets and behaviors well downstream, as well as 
temporally and spatially distinct from the early acute-phase FBR mast cell and leukocyte 
initiating reactivities around the implant.  
Mast cells (MC) play a critical role in mediating acute tissue inflammatory 
responses. Located perivascularly throughout all tissues MCs are mobilized during any 
inflammatory response [36].  MC degranulation of histamine and other pro-inflammatory 
mediators including heparin, cytokines (e.g., TNF-alpha), chemokines, and many 
proteases together with fibrinogen adsorption are recognized as powerful inducers of 
acute inflammatory responses to implanted biomaterials [37, 38].  MC-released 
cytokines and chemotaxis along with histamine and serotonin release result in 
vasodilation and increased recruitment of phagocytes to the implant site. Their 
connection with the foreign body reaction is well recognized [26, 27, 39].  Specific to 
CGMs, Klueh et al. [40] have recently compared MC behavior in vivo on CGM sensor 
implant performance in both wild-type and MC-deficient mice. Significantly, they 
confirmed using CGM signal-to-noise ratio (S/N) and analyte response time as a function 
of implant time that MCs play a major role in the host FBR around CGMs.  Importantly, 
this effect was linked to subsequent fibrous capsule formation around the CGM that 
impedes sensor function [40]. 
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Elucidating how MCs orchestrate the host FBR has been elusive.  One new clue 
is that stem cell factor (SCF), the ligand of the MC-specific c-KIT tyrosine kinase 
receptor, is an important growth factor for MC survival, proliferation, differentiation, and 
degranulation processes [41]. The link between the MC-specific SCF/MC c-KIT pathway 
and the intensity of acute phase of the inflammatory response appears critical in MC 
function and degranulation reactions [42]. 
Here, we describe use of the newly screened tyrosine kinase inhibitor (TKI), 
masitinib, shown effective in inhibiting the SCF receptor, c-KIT, on MCs.  Masinitib offers 
potent control of MC reactivity [43, 44] by binding competitively to the ATP-binding c-KIT 
receptor, blocking its critical tyrosine kinase signaling activity.  Importantly, this 
pharmacological action stabilizes mast cells from degranulating or activating.  
Use of masitinib to control MC activation in the context of the FBR is unknown.  We 
proposed that its pharmacology could be exploited to benefit CGM function by 
formulation into a local release coating applied to CGM sensors and implanted 
subcutaneously in wild type C57BL/6 mice and monitored for CGM function in situ for 21 
days. 
5.3 Materials and Methods 
5.3.1 Materials  
Poly(lactic-co-glycolic acid) (PLGA) was purchased from Surmodics Biomaterials 
(now Evonik Biomaterials, USA), and masitinib was purchased from Selleck Chemicals 
(Houston, USA).  Wild-type C57BL/6 mice (12-week old males) were purchased from 
Jackson Laboratories (Bar Harbor, USA) for the in vivo studies. A multichannel 
potentiostat (CH Instruments model CHI1000C, Austin, USA) was used to interface with 
CGM sensors to record their in vitro and in vivo responses. All chemicals were 




5.3.2 Glucose sensor surface modification, drug loading, and in 
vitro testing 
  Modified Freestyle Navigator™ sensors (Abbott Diabetes Care, Alameda, CA) 
were used for this study. Sensors were coated with a PEG matrix-PLGA microsphere 
composite formulation as described previously [45, 46]. Briefly, PLGA microspheres 
containing masitinib were prepared using solvent-evaporation method and then mixed in 
aqueous PEG solution and the resulting formulation is coated around the commercial 
CGM sensors cryogenically using a 2-part aluminum mold.  Control implant coatings 
were prepared with a similar process with identical ingredients except masitinib. 
A sample of 3 sensors were tested before and after coating in 1x phosphate 
buffered saline solution (PBS) at 37°C with both 0 and 90 mg/dL glucose concentration 
to evaluate coating perturbations on the CGM sensor performance in terms of glucose 
sensitivity and response time. 
5.3.3 Sensor implantation procedure  
Sensors were implanted with slight modifications from the procedures described 
by Klueh et al. [40, 47, 48].  Each sensor is tested in 1x PBS at 90 mg/dl glucose to 
provide in vitro calibration values before murine implantation.  Mice were anesthetized 
with 2% isofluorane administered through a nose cap. Fur on back of each animal was 
clipped in an area of 6×4 cm2 and cleaned with povidone-iodine solution to create an 
aseptic location for sensor implantation. A sterile 18G needle was then used to create a 
point-of-insertion for the CGM sensor. Corneal scissors were used to blunt-dissect the 
pocket to create space for the sensor. A CGM sensor is inserted into the pocket through 
the point-of-insertion. The sensor is then glued to the skin using NewskinTM Skin Glue 
and secured with surgical staples.  A thin strip of Velcro™ is then strapped around the 
animal’s abdomen to secure the CGM sensor and avoid relative motion against the skin 
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at its percutaneous entry.  The animals were allowed to recover and housed individually 
in modified cages to enable securing the sensor wiring and were provided with food and 
water ad libitum. Sensors were then connected to individual recording channels on the 
multipotentiostat to continuously monitor glucose levels for a period of 21 days. 
5.3.4 Data monitoring and processing  
Glucose response current was collected every 60 seconds from the sensors. 
Moving average glucose values were processed with 120-minute frequency to smoothen 
the response and to observe the trends over a 21-day period. Raw data are plotted and 
the 120-minute moving average data are overlapped onto the plot.  
Daily maximum and minimum values for each glucose sensor were recorded and 
plotted with respect to time to observe and better understand the trends of the glucose 
sensor data. 
5.3.5 Histological evaluation  
Animals were euthanized and tissue beds surrounding the sensor implant site 
were harvested at the end of the time period and processed for histological analysis. 
Tissue slides were fixed in 10% neutral buffered formalin and sent to Associated 
Research and University Pathologists (ARUP, USA) labs for staining with Hematoxylin 
and Eosin (H&E), and Masson’s Trichrome (MTC) stains. Tissue sites were evaluated 
for fibrous encapsulation around implant sites from multiple sites on multiple slides for 
each implant.  
5.4 Results 
5.4.1 CGM sensor modification   
Clinically approved CGM sensors were coated with the PEG-PLGA microsphere 
composite formulation shown to dissolve completely within a few minutes when exposed 
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to PBS [45]. This leaves the PLGA microspheres deposited in the tissue bed around the 
sensor without any sensor interference from a coating [45]. Figure 5.2A shows both the 
PEG/PLGA composite coated and uncoated sensors. Modified animal housing cages 
allow wire tethers to extend from the implanted sensors in the animals to the 
multichannel potentiostat, as shown in Figures 5.2B and 5.2C. Sensor testing before and 
after polymer coating exhibited less than 10% (i.e., +4.9 to -9.1%) change in response at 
90 mg/dl glucose challenge in PBS at 37°C (shown in Figures 5.3A and 5.3B). This 
minor change is attributed to slight variations resulting from different in vitro temperature 
or experimental variables. 
5.4.2 CGM response 
Figure 5.4 shows implant CGM in vivo response from masitinib-releasing and 
control implants. Raw sensor output in nA is plotted together with a calibration axis 
(double right y-axis) since each sensor exhibited different calibrations. Measured 
glucose values ranged from 100–200 mg/dl over the first few days. All sensors exhibit an 
initial drop in glucose values for the first few days after implantation (i.e., sensor burn in).  
Sensor response fluctuates as a result of variations in normal animal activity (i.e., 
glycogen release) and in blood glucose due to food intake. Figure 5.4A shows the 
response from a drug-releasing implant that is relatively consistent and stable compared 
to control implant output. CGM response from drug-releasing implants seen from the 
120-minute moving average data is consistent over the implantation period whereas a 
marked loss of glucose sensitivity is observed in control sensors, as seen in Figures 
5.4B-5.4D. 
5.4.3 Histology analysis  
Analysis of Masson’s trichrome-stained histology tissue sites from 21-day implant 
harvests shows very little inflammation around drug-releasing implant sites and 
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comparatively higher amounts of fibrosis around control implants as characterized by the 
blue collagen staining seen in Figure 5.5A and 5.5B.  A thin layer of collagen 1-2 cell 
layers thick could be observed around drug-releasing implants whereas a uniform region 
of collagen deposition was observed in control implants.  
5.5 Discussion 
Strategies to enable continuous and reliable CGM sensor response in tissue 
sites for longer durations than existing implantation times (e.g., currently ~1 week) is 
currently a major challenge plaguing long-term CGM performance. Several combination 
device strategies have sought to use on-board drug delivery from the sensor to 
“condition” the implant site pharmacologically and enhance the local sensor-tissue 
interface [24-30]. Tissue mast cells have been shown to be important to eliciting the FBR 
around CGM sensors during the acute inflammatory response stage, affecting their 
tissue site performance [40].  Targeting the SCF/c-KIT pathway to inhibit degranulation 
and activation pathways in tissue mast cells around implantable CGM sensors exploits 
the pharmacology of the TKI, masitinib.  Previous work has shown reductions in the 
fibrous capsule thickness formed around masitinib-releasing nonfunctional sensor model 
implants [45]. That this observed reduced fibrosis around masitinib-releasing implants 
translates to improved CGM response in vivo was pursued in this study. 
PEG-PLGA microsphere composite coatings were designed to dissolve within 
minutes of implantation to allow unhindered glucose access to the sensor surface [45, 
46]. This coating shows no significant effect on the sensors’ glucose sensitivity: less than 
10% change is observed in sensor signal outputs tested in vitro before and after coating 
in a glucose standard.  The coating also does not appear to affect sensor performance in 
the in vivo studies as well. A normal “break-in” period is observed in sensor response 
from control implants, during which sensitivity drops immediately after implantation (see 
  
115 
Figure 5.4) as has been previously observed in several studies [7, 12, 13]. Drug-
releasing implants show relatively reduced sensor break-in responses during this early 
implantation period (data not shown), suggesting lower intensities of tissue inflammatory 
responses around these implants during acute stages.  
Sensor response over the entire duration of the 21-day study, characterized by 
the moving average data (Figure 5.4), shows a clear distinction in responses between 
drug-releasing and control implants. Drug-releasing implants exhibit stable glucose 
values with consistent, periodic fluctuations attributed to animal physical activity and 
food consumption, whereas in the control implants loss of sensor function is observed in 
various forms. For example, data from sensor 413C shown in Figure 5.4B exhibit a clear 
change in glucose fluctuations, specifically after day 14, which can be attributed to 
limited glucose availability to the sensor. 
Maximum and minimum glucose value trend plots shown in Figure 5.5 provide a 
better understanding to CGM response for a given sensor. Data shown in Figure 5.5A 
and 5.5C from the control implants show a consistent degradation of sensor signal as 
evidenced by the decreasing difference between the maximum and minimum values for 
a given time point. The moving sensor data and the daily maximum and minimum trend 
data suggest that the CGM sensors get decreasing access to environmental glucose 
over the duration of the study. Control CGM implants exhibit a greater loss in glucose 
sensitivity compared to the durg-treated CGM sensors. This loss in sensitivity can be 
attributed to the steric hindrance of the fibrous capsule surrounding the implants and can 
also be attributed to the consumption of glucose by the various cell types involved in 
mediating the foreign body response to the implants.  
Histology evaluation shows reduced inflammation and collagen deposition 
around masitinib-releasing implants compared to control implants at 21 days (Figure 
5.6). The effect of masitinib in targeting fibroblasts via mast cell-stabilization and through 
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the inhibition of fibroblast growth factor receptor 3 (FGFR3) might contribute to this 
collagen difference [43, 46]. Klueh et al. [40] recently reported similar reduced fibrosis 
around subcutaneous implants in mast cell-deficient sash mouse models.  
Use of the mouse subcutaneous implant model to evaluate the effects of the host 
FBR on CGM performance is more appropriate for short-term investigative studies than 
longer-term implants due to notable dissimilarities in their dermal physiology compared 
to humans. Intrinsically thin dermis combined with the presence of a muscle layer 
adjacent to the dermis without significant cutaneous adipose in these animals 
contributes to increased mechanical micromotion from subcutaneous muscle twitches 
upon implantation that is minimal or absent in human tissues.  This murine muscle 
micromotion can be further exacerbated by tethering the external portion of the CGM 
implant to the recording device and allowing the animals free movement while tethered 
for 21 days [49].  The relative size of the actual CGM implant approved for human use 
compared to the animal’s body can even further result in micromotion-associated tissue 
responses that are independent of the implantation and tethering process. Lastly, human 
CGMs are recommended clinically to be best placed in subdermal adipose tissue in 
humans [50], a situation very unlikely in the murine model given their lack of such 
adipose in skin.   All of these differences are likely contributing factors to fluctuations 
observed in the implanted CGM sensor outputs. Evaluating the CGM sensors and 
effects of local drug release targeting mast cell-implant activation responses relevant to 
the FBR might be more accurately performed in porcine models with their dermal tissue 
physiology similar to humans.   
5.6 Conclusions 
CGMs modified to release the TKI inhibitor, masitinib, exhibit stable glucose 
readings in vivo.  Sensor performance is improved providing improved glucose sensing 
  
117 
in the presence of masitinib. Reduced glucose sensor sensitivity can be attributed to the 
consumption of glucose by cells surrounding the implant site. Masitinib-releasing PEG-
PLGA microsphere coating on CGM sensors show reduced collagen formation around 
the implant site, suggesting that local tissue mast cell and fibroblast functions are 
affected by the drug. Implant-associated micromotion can be causing the fluctuations in 
the sensor response. 
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Figure 5.1: Conceptual depiction of the collagenous encapsulation of implanted CGM sensors 




Figure 5.2: Sensor and experimental setup. A) CGM sensors before and after coating, B) 
modified cage for housing mice with CGM implants during the long-term 21-day implant study, 








Figure 5.3: Sensor response to in vitro dynamic glucose change from 0 to 90 mg/dl: A) before 









Figure 5.4: Implanted CGM sensor response monitored in real-time for 21 days by direct 
wired CGM implants in murine subcutaneous sites: A) Drug-releasing CGM, and B) control 










Figure 5.5: Plot showing daily maximum and minimum values of CGM sensor response. A) 








Figure 5.6: H&E stained tissue sites for A) control (blank), and B) drug-releasing coated 
implants; Masson’s trichrome stained tissue sites for: C) control (blank), and D) drug-releasing 
coated implants explanted after 21 days in murine subcutaneous sites. ‘*’ shows the location 
of the implant site. Scale 200 µm. 
CHAPTER 6 
SUMMARY OF RESEARCH AND SUGGESTED FUTURE WORK 
This closing chapter presents a summary of the major results in addressing the 
motivation for the research, and selected technical recommendations for future studies. 
Diabetes mellitus is an epidemic characterized by chronic hyperglycemia resulting from 
insufficient production or tolerance to insulin. Nearly 350 million people (5% of world 
population) suffer from diabetes worldwide [1], including the 25.8 million Americans 
(8.3% of the population) who require regular glucose monitoring.  Treatment has direct 
and indirect costs of about $218 billion annually (2007) [2]. Tight regulation of blood 
glucose has been convincingly shown to reduce diabetes morbidity and mortality [3], 
leading to a standard of care that demands intensive glucose monitoring.  
Alternatives to the current CGM sensor implants lasting less than a week need to 
be developed for long-term reliable glucose monitoring that would enable the 
development of closed-loop insulin delivery systems that are extremely beneficial to 
younger patients. Long-term fully implantable sensors will improve the device 
performance while reducing the costs and discomfort associated with needle type 
percutaneous implants. Fully implantable sensors eliminate the problems associated 
with percutaneous implants such as infection of the wound site, fibrosis associated with 
tethering of the implants, adhesion problems of the transmitter base to the epidermis, 
etc. Problems with wireless charging and telemetry exist with the conception of such 
systems and can be adopted from other existing devices such as pacemakers and 
improvements in low power wireless data communication technology. The successful 
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culmination of this project would be the combination of a fully implantable sensor device 
and an efficient targeting of early phase tissue response to delay and/or modify FBR and 
the associated fibrous encapsulation.  
6.1 Chapter 3: Modulation of the Foreign Body Response to 
Implanted Sensor Models Through Device-based Delivery of 
the Tyrosine Kinase Inhibitor, Masitinib 
6.1.1 Motivation for this work 
Continuous glucose monitoring (CGM) sensors are adversely affected by the 
host foreign body response. Fibrous encapsulation resulting from the FBR degrades the 
sensing ability of CGM sensors by “walling-off” the sensor from the essential analytes 
such as glucose and oxygen. Mast cells among several other cell types and cell-
signaling molecules are known to play a key role in mediating the formation of this 
fibrous capsule [4]. Mast cells play a critical role in the acute inflammatory response by 
degranulating and secreting key cell-signaling molecules, including vasodilators like 
histamine and serotonin, and inflammatory cell recruiting cytokines like IL-4 and IL-13 [4-
8]. We hypothesized that targeting mast cell degranulation would result in a less intense 
FBR and hence could be used to improve the longevity and performance of CGM 
sensors. To test our hypothesis, we chose masitinib – a newly developed tyrosine kinase 
inhibitor to target mast cell degranulation via the targeting of c-KIT receptor known to be 
essential for mast cell survival, proliferation, and degranulation [9, 10]. 
6.1.2 Summary of research work 
Polyester fibers were chosen as the sensor model implants that would mimic the 
dimensions and material properties of a CGM sensor. Masitinib release in the local 
tissue surrounding the implant could be efficiently managed by the formulation of a local 
delivery mechanism. Poly (D,L-lactic-co-glycolic acid) (PLGA) is a well-studied 
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biodegradable polymer commonly commercially used as a drug delivery vehicle for 
various agents (e.g., peptides, hormones, siRNA, DNA, VEGF, protein therapeutics, and 
small molecules) [11-16]. PLGA of three different intrinsic viscosities was selected as the 
drug carrier and was formulated into 5-20 µm diameter microspheres to avoid 
phagocytosis. In vitro release kinetics were determined for 30 days to characterize the 
release profiles of the drug. The microspheres were then combined with an aqueous 
solution of PEG-PEO mixture that was chosen as the matrix material to transiently hold 
microspheres around the implants until implantation. The PEG-PLGA microsphere 
coating was fabricated around the implants using mold coating techniques. The coated 
sensor models were then implanted in murine subcutaneous tissue for 14, 21, and 28 
days and the tissue surrounding the implant sites was analyzed using histology to 
evaluate the effect of mast cells on FBR.  
6.1.3 Critical assessments  
A coating formulation that could transiently contain drug-releasing microspheres 
around the implant could be developed. The coating design allowed it to completely 
disintegrate in bodily fluids upon implantation, thereby releasing the microspheres in the 
vicinity of the implant and enabling unhindered implant-tissue interactions. Histology 
analysis showed complex inflammatory cell densities around the implantation site. The 
complexity can be attributed to the presence of two distinct implant types, i.e., a 
monolith, low surface area polyester fiber sensor model, and a low density, high surface 
area, and foam-like disintegrated PEG-PLGA microsphere coating. The presence of 
these distinct implant types would cause the FBR to the implants to proceed 
independently with two separate timelines for the various cell arrivals causing a 
complicated inflammatory cell density. However, the capsule thickness assessments 
around the sensor model implants show a clear and significant reduction in the thickness 
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values around drug-releasing implants compared to the control implant sites. These 
results would suggest that mast cells play an important role in mediating capsule 
formation around implants. Although the results show a clear decrease in capsule 
thickness around the drug-releasing implant sites, it is unclear if these capsules are 
permeable to glucose and oxygen – the two most important molecules for the detection 
of glucose, to the sensor surface. 
6.2 Chapter 4: Foreign Body Response to Implanted 
Biomaterials in a Mast Cell-deficient Kitw-Sh Murine Model 
6.2.1 Motivation for this work 
In Chapter 2, we had tested the effect of masitinib-releasing implants on the 
tissue response and the subsequent fibrous capsule resulting from it. Masitinib is a 
potent inhibitor of c-KIT receptor that is critical for mast cell survival. Therefore, 
masitinib-releasing implants are expected to downregulate mast cell degranulation and 
result in lower fibrosis of implants. We have seen evidence for this downregulation of 
mast cell activity in the form of reduced capsule thickness around masitinib-releasing 
implants in wild-type mice. To ensure that masitinib is only affecting mast cell activity, we 
needed to test the drug in mast cell-deficient sash mouse model. By testing both control 
and drug-releasing implants in the sash mouse model, the effect of masitinib could be 
understood on the modulation of FBR. Additionally, FBR can be studied in the absence 
of mast cells. 
6.2.2 Summary of research work 
In this study, polyester fiber sensor models were coated with the PEG-PLGA 
microsphere coating and implanted in mast cell-deficient sash mouse model for 14-, 21-, 
and 28-day time points. At the end of each time point, the animals were euthanized and 
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the tissue bed surrounding the implant sites was harvested and histological analysis was 
performed.  
6.2.3 Critical assessments 
Masitinib release in sash mice did not seem to effect the capsule formation 
around the implant site. Capsule thickness values around control and drug-releasing 
implants seemed to be similar and the inflammatory cell densities were found to be 
comparable. Capsule thickness assessment has also shown that there is no comparable 
increase in the fibrosis among the 14-, 21-, and 28-day implant sites. However, the 
capsule thickness values around drug-releasing implants around sash mice were found 
to be significantly higher when compared to those in wild-type mice. These results 
indicate that the modulation of FBR in the absence of mast cells has an alternative 
pathway and that the fibrosis manifests earlier than in mast cell sufficient mice and 
remains largely unchanged for long-term implants. 
6.3 Chapter 5: Local Release of Masitinib Affects Implantable 
Continuous Glucose Sensor Performance  
6.3.1 Motivation for this work 
In Chapters 2 and 3, the effect of masitinib and the role of mast cells in 
modulating FBR and the resulting fibrosis were evaluated using sensor models. In this 
chapter, we designed a study to test commercial CGM sensors that are coated with 
masitinib-releasing formulation in wild-type mouse for 21 days. The goal of this study 
was to examine any performance improvements in the masitinib-coated CGM response 
over a control. Commercial CGM sensors are have FDA-approved implantation times 
limited to less than a week. The purpose of this study was to examine the possibility of 
improvements in reliability of glucose sensing values over the FDA-approved periods. 
This would culminate the work proposed in this dissertation by confirming that targeting 
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tissue mast cells around the implantation site of a CGM sensor would affect its long-term 
performance. 
6.3.2 Summary of research 
In this study, modified Abbott Freestyle Navigator sensors were used as the 
implants. The PEG-PLGA microsphere coating process was modified for the CGM 
sensors. PEG-PLGA microsphere-coated sensors were tested before and after the 
coating process to evaluate the effects of the coating process on the sensor response in 
terms of sensitivity and response times to glucose changes in vitro. The coated sensors 
were then implanted in wild-type C57BL/6 mice for 21 days. These time points are ~5-7x 
the FDA-approved implantation time for the sensor. At the end of the time points, the 
tissue surrounding the sensor implant site was harvested and analyzed using histology 
for capsule thickness. A sample of implanted sensors were tested postmortem for the 
respective time points to evaluate their performance 
6.3.3 Critical assessments 
CGMs modified to release the TKI inhibitor, masitinib, exihibit stable glucose 
readings in vivo.  Sensor performance is improved providing consistent glucose sensing 
in the presence of masitinib. Masitinib-releasing PEG-PLGA microsphere coating on 
CGM sensors show reduced collagen formation around the implant site, suggesting that 
local tissue mast cell and fibroblast functions are affected by the drug. Implant-
associated micromotion can be causing the fluctuations in the sensor response. 
6.4 Suggested Future Work 
6.4.1 Hollow fiber implants 
From our studies, we have shown that fibrosis and fibrous capsule formed 
around implants is being affected by the use of masitinib to target mast cells. However, 
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evaluating the nature of the capsule that is formed around drug-releasing implants is 
essential to understanding the ability of sensor implants to perform for longer durations 
under mast cell inactivity. A study designed specifically to understand the nature and 
permeability of the capsule could involve the use of a microdialysis hollowfiber probe 
(Cuprophan, outer diameter, 0.25 mm, inner diameter, 0.20 mm; length, 15 mm) can be 
coated with masitinib-releasing formulation and implanted subcutaneously in a murine 
model. Microdialysis can be performed in these implants for extended periods to ensure 
glucose transport through the capsule formed in the presence of masitinib to evaluate 
the permeability of the capsule. Each animal can be implanted with two microdialysis 
catheters – one control and one drug-releasing implant. This experiment would A) help 
in understanding the nature of the capsule formed and B) examine the period of time 
that the drug can be effectively used to reduce the FBR. At the end of the study, 
fluorescently-labeled glucose 2-NBDG (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose) can be injected into the hollow fiber to visually examine the permeability 
of the capsule during histology analysis [17]. The extent of dye-penetration into the 
surrounding capsule can be characterized to further understand the nature of the 
capsule. 
6.4.2 Bone marrow-derived mast cell injections 
To test our hypothesis that inhibiting mast cell degranulation results in a reduced 
FBR, we have conducted studies with local delivery formulations of masitinib in both 
mast cell sufficient (Chapter 3) and deficient (Chapter 4) mouse models. To further prove 
the role of mast cells, we could inject in vitro-cultured bone-marrow derived tissue mast 
cells at the CGM sensor implant sites. A similar experiment in mast cell-deficient sash 
mice implanted with CGM sensors has shown a precipitous drop in glucose 
measurements within a few days of mast cell injections [18]. Bone marrow derived mast 
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cells can be culture as described in [18, 19]. Injections of 104 to 105 cells in pyrogen free 
saline at the implant site of the sensor could be performed. CGM response can be 
monitored for one week after the injection of the mast cells to observe any recovery from 
mast cell injection effects. 
6.4.3 Dose escalation studies and the effect of combination of 
masitinib and anti-inflammatory drugs 
The results from this work show significant reduction of fibrous capsule 
thicknesses around masitinib-releasing implants. The dosage used in these studies was 
empirical targeting 200 µm thick tissue surrounding the implant site. A randomized dose-
escalation study to investigate the dose-response relationship of masitinib could be 
investigated. Different dosages of 23 µg/implant and 35 µg/implant (i.e., 2x and 3x the 
current dosage) could be used to evaluate the result of increased drug dosing on the 
fibrous encapsulation. These studies will give the appropriate dose to mitigate FBR for a 
given time point. 
Mouse models are difficult to handle with a tethered wired sensor setup due to 
their relatively small body size with respect to the sensor size. Current CGM sensors 
detect glucose levels in the interstitial fluid in subcutaneous adipose tissue and the 
mouse model does not possess sufficient adipose tissue for accurate CGM sensor 
functioning [20, 21]. Zucker diabetic fatty (ZDF) rats are a commonly used animal model 
in diabetes studies [22].  ZDF rats provide sufficient adipose tissue for CGM sensing and 
are easier to handle compared to C57Bl/6 mice for long-term CGM testing.  
In this dissertation work, we have focused on targeting mast cell degranulation 
that is widely recognized as a key initiator and orchestrator of host-mediated FBR to 
implants. However, the release of masitinib does not directly target inflammation and 
inflammatory cells. Keeping this in view, a future experiment can be designed that uses 
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a drug formulation containing a combination of masitinib and an anti-inflammatory drug. 
Aspirin is an anti-inflammatory drug that has shown to reduce fibrosis and inflammation 
around the implant sites [23]. PLGA microsphere formulations of both dexamethasone 
and aspirin have been previously developed [24]. Quantified amounts of aspirin PLGA 
microspheres along with masitinib PLGA microspheres can be coated onto CGM 
implants and their combined effect on the FBR and resulting fibrosis can be studied. It 
also needs to be verified if the combination of these drugs counteracts each other’s 
effect [25]. 
Estimating an appropriate number of test subjects to observe statistically 
significant differences in responses from control and drug-treated groups is very 
important to obtain relevant results. Sample size for CGM sensor studies in mice can be 
calculated based on the capsule thickness data obtained from model implants in wild 
type mice studies. Assuming a 20% difference in the means of capsule thickness values 
among the control and treated groups, and a 90% power with a p-value of 0.05 (from the 
table below), the needed sample size can be calculated using Lamorte’s sample size 
calculator to be 15 animals per group, i.e., 30 animals for control and drug-treated 
groups for a single time point of 21-days. The detailed calculation is shown in Table 6.1. 
6.4.4 Sterilization methods 
The work done in this dissertation used aseptic processes to reduce the 
possibility of bacterial contamination of the implants that has been confirmed with LPS 
experiments. However, there is a need to develop a reliable sterilization method to 
reduce the bio burden of these implants. Thermal methods of sterilization are unusable 
for these implants given their polymeric constituents, a majority of which are irreversibly 
damaged at high temperatures needed for such sterilization methods. Ethylene oxide 
and sterrad methods tried during our studies have shown to collapse the porous 
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structure of the coating that would result in slower dissolution of the coating components. 
Radiation sterilization is known to result in reducing the molecular weights and 
accelerating the degradation rates of PLGA [26]. A low temperature, radio-frequency 
glow discharge (RFGD) plasma treatment sterilization method was developed for 
treating polyester devices [27]. While the RFGD plasma was shown to induce surface 
cross-linking or branching of the polymer, it did not affect polymer crystallinity, 
mechanical properties, or overall melting temperature [28]. The sterilization efficiency of 
plasma gas was demonstrated by a 105 reduction of bacteria, bacterial endospores, 
yeast and bacterial viruses within 90 s of exposure to an atmospheric uniform glow 
discharge plasma [29], indicative of a similar sterilization efficiency to that of ETO and 
gamma. RFGD plasma sterilization at 100 W for 4 minutes has shown no volume change 
and a slight increase in the molecular weight of PLGA scaffolds [30] and can be adopted 
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Table 6.1: Sample size estimation for future in vivo studies using Lamorte’s sample size 
calculator 
 
 
 
